

J-Y Blay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1048141/publications.pdf>

Version: 2024-02-01

1,119
papers

72,798
citations

477

133
h-index

1285

231
g-index

1250
all docs

1250
docs citations

1250
times ranked

49646
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. <i>International Journal of Cancer</i> , 2022, 150, 645-653.	2.3	9
2	Gastrointestinal stromal tumours: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33.	0.6	213
3	New therapeutic advances of bone sarcomas. , 2022, , 755-766.		0
4	Neoadjuvant chemotherapy in highâ€“risk soft tissue sarcomas: A Sarculatorâ€“based risk stratification analysis of the ISGâ€“STS 1001 randomized trial. <i>Cancer</i> , 2022, 128, 85-93.	2.0	46
5	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	3.2	18
6	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I openâ€“label, dose escalation study. <i>International Journal of Cancer</i> , 2022, 150, 993-1006.	2.3	28
7	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfilER trial. <i>Medical Oncology</i> , 2022, 39, 4.	1.2	3
8	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. <i>Cancer Treatment Reviews</i> , 2022, 102, 102312.	3.4	29
9	Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfilER program. <i>Translational Oncology</i> , 2022, 15, 101266.	1.7	3
10	Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , The, 2022, 23, 53-64.	5.1	165
11	Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox. <i>European Journal of Cancer</i> , 2022, 162, 128-129.	1.3	2
12	Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 382-393.	1.5	18
13	Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study. <i>Radiotherapy and Oncology</i> , 2022, 168, 95-103.	0.3	3
14	Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. , 2022, 10, e003687.		15
15	Global Patient Involvement in Sarcoma Careâ€“A Collaborative Initiative of the Connective Tissue Oncology Society (CTOS) & Sarcoma Patients EuroNet (SPAEN). <i>Cancers</i> , 2022, 14, 854.	1.7	2
16	Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients. <i>European Journal of Cancer</i> , 2022, 165, 174-183.	1.3	14
17	Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i> , 2022, 54, 412-429.	1.0	104
18	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	7.7	10

#	ARTICLE	IF	CITATIONS
19	Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond. <i>Cancers</i> , 2022, 14, 1064.	1.7	25
20	Improving at a nationwide level the management of patients with sarcomas with an expert network. <i>Annals of Oncology</i> , 2022, 33, 659-661.	0.6	9
21	Impact of Limited E-Health Literacy on the Overall Survival of Patients With Cancer. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100174.	1.0	4
22	Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 1087-1097.	3.2	22
23	Lack of Prognostic Value of <i>CTNNB1</i> Mutation Profile in Desmoid-Type Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4105-4111.	3.2	11
24	Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG). <i>ESMO Open</i> , 2022, 7, 100402.	2.0	8
25	Molecular Mechanisms of Kaposi Sarcoma Development. <i>Cancers</i> , 2022, 14, 1869.	1.7	10
26	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2479-2490.	0.8	15
27	Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. <i>ESMO Open</i> , 2022, 7, 100419.	2.0	7
28	Overall and net survival of patients with sarcoma between 2005 and 2010: Results from the French Network of Cancer Registries (FRANCIM). <i>Cancer</i> , 2022, 128, 2483-2492.	2.0	4
29	Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials. <i>ESMO Open</i> , 2022, 7, 100425.	2.0	2
30	Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study. <i>Clinical Cancer Research</i> , 2022, 28, 1765-1772.	3.2	17
31	SELNET clinical practice guidelines for bone sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103685.	2.0	12
32	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 "CaboGIST". <i>Acta Oncologica</i> , 2022, 61, 663-668.	0.8	1
33	Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019. <i>International Journal of Cancer</i> , 2022, 151, 1345-1354.	2.3	5
34	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
35	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks Outcome?. <i>Cancers</i> , 2022, 14, 2620.	1.7	4
36	Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcoma. <i>Radiotherapy and Oncology</i> , 2022, 173, 55-61.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial). <i>BMC Cancer</i> , 2022, 22, .	1.1	6
38	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	1.3	4
39	Editorial: precision medicine of sarcomas and aggressive connective tissue tumours: from one-size-fits-all to haute couture. <i>Current Opinion in Oncology</i> , 2022, 34, 320-321.	1.1	0
40	CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. <i>European Journal of Cancer</i> , 2021, 143, 78-87.	1.3	41
41	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 132-141.	1.9	9
42	Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. <i>Cancers</i> , 2021, 13, 423.	1.7	12
43	Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. <i>BMC Cancer</i> , 2021, 21, 89.	1.1	20
44	Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models. <i>Cells</i> , 2021, 10, 399.	1.8	4
45	Continue rare cancers collaboration with European Reference Networks after Brexit. <i>Lancet, The</i> , 2021, 397, 793.	6.3	2
46	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. <i>Bulletin Du Cancer</i> , 2021, 108, 163-176.	0.6	7
47	Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. <i>ESMO Open</i> , 2021, 6, 100044.	2.0	15
48	Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. <i>ESMO Open</i> , 2021, 6, 100037.	2.0	8
49	Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. <i>PLoS ONE</i> , 2021, 16, e0246958.	1.1	131
50	Gastrointestinal stromal tumours. <i>Nature Reviews Disease Primers</i> , 2021, 7, 22.	18.1	169
51	European Reference Networks: challenges and opportunities. <i>Journal of Community Genetics</i> , 2021, 12, 217-229.	0.5	21
52	ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. <i>Cancers</i> , 2021, 13, 2151.	1.7	10
53	Inpatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. <i>ESMO Open</i> , 2021, 6, 100072.	2.0	11
54	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)†. <i>Annals of Oncology</i> , 2021, 32, 533-541.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 7854-7863.	0.7	19
56	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
57	Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. <i>European Journal of Cancer</i> , 2021, 147, 164-169.	1.3	13
58	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021, 21, 631.	1.1	14
59	ASO Visual Abstract: An Analysis of Differentiation Changes and Outcomes at the First Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 490-491.	0.7	4
60	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	2.0	65
61	Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. <i>ESMO Open</i> , 2021, 6, 100134.	2.0	51
62	NTRK fusion in soft tissue sarcomas harboring MDM2/CDK4 amplification: three case reports. <i>Annals of Oncology</i> , 2021, 32, 813-814.	0.6	6
63	Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer center. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1793-1804.	1.0	5
64	Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. <i>British Journal of Cancer</i> , 2021, 125, 658-671.	2.9	20
65	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , 2021, 39, 1587-1597.	1.2	15
66	Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. <i>Targeted Oncology</i> , 2021, 16, 485-492.	1.7	3
67	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021, 150, 108-118.	1.3	16
68	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021, 150, 232-239.	1.3	11
69	TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfILER Precision Medicine Trials. <i>Cancers</i> , 2021, 13, 3362.	1.7	6
70	Soft tissue and visceral sarcomas: ESMO "EURACAN" GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up†. <i>Annals of Oncology</i> , 2021, 32, 1348-1365.	0.6	381
71	A French cohort for assessing COVID-19 vaccine responses in specific populations. <i>Nature Medicine</i> , 2021, 27, 1319-1321.	15.2	14
72	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	5.0	31

#	ARTICLE	IF	CITATIONS
73	Metabolic landscapes in sarcomas. <i>Journal of Hematology and Oncology</i> , 2021, 14, 114.	6.9	10
74	Sarcoma management: expertise and balance. <i>Future Oncology</i> , 2021, 17, 1-1.	1.1	1
75	Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients. <i>Annals of Oncology</i> , 2021, 32, 1443-1444.	0.6	27
76	Keeping the balance, the true major goal in advanced sarcoma. <i>Future Oncology</i> , 2021, 17, 11-16.	1.1	1
77	A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. <i>Annals of Oncology</i> , 2021, 32, 1034-1044.	0.6	24
78	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. <i>Oncologist</i> , 2021, 26, e2053-e2060.	1.9	19
79	European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. <i>ESMO Open</i> , 2021, 6, 100174.	2.0	21
80	Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor "Checkpoint inhibition: protecting against or predisposing for second primary tumors?" by K. P. M. Suijkerbuijk, A. M. M. van Eijs. <i>Annals of Oncology</i> , 2021, 32, 1055-1057.	0.6	1
81	Locally aggressive rarely metastasizing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network. <i>European Journal of Surgical Oncology</i> , 2021, , .	0.5	2
82	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-ST5 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	1.9	2
83	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. <i>Clinical Cancer Research</i> , 2021, 27, 6737-6748.	3.2	12
84	LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study. <i>Annals of Oncology</i> , 2021, 32, S1335-S1336.	0.6	10
85	1540P Ripretinib as 4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study. <i>Annals of Oncology</i> , 2021, 32, S1120-S1121.	0.6	7
86	1544P Soft tissue sarcoma (STS) incidences and clinical characteristics are significantly different between different geographic and ethnic populations. <i>Annals of Oncology</i> , 2021, 32, S1122.	0.6	0
87	1551P Efficacy of early phase trials for soft-tissue sarcoma patients: The Centre Léonard and Gustave Roussy experience. <i>Annals of Oncology</i> , 2021, 32, S1126.	0.6	0
88	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRα Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021, 27, 6333-6342.	3.2	25
89	1522MO Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF). <i>Annals of Oncology</i> , 2021, 32, S1112.	0.6	0
90	1750P Molecular genotyping in refractory thyroid cancers: Results of a European survey. <i>Annals of Oncology</i> , 2021, 32, S1206-S1207.	0.6	2

#	ARTICLE	IF	CITATIONS
91	1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capitalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial. <i>Annals of Oncology</i> , 2021, 32, S1111.	0.6	3
92	Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19. <i>Lancet Microbe</i> , The, 2021, 2, e424.	3.4	11
93	Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021, 157, 527-528.	1.3	1
94	822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy. <i>Annals of Oncology</i> , 2021, 32, S772.	0.6	0
95	Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536.	0.6	150
96	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021, 156, 12-23.	1.3	26
97	Genetic Analysis in Anal and Cervical Cancer: Exploratory Findings About Radioresistance in the ProFiLER Database. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 515-520.	1.0	0
98	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	0.7	26
99	Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum. <i>Spine</i> , 2021, 46, 277-284.	1.0	28
100	Rare bone sarcomas: a retrospective analysis of 145 adult patients from the French Sarcoma Group. <i>International Journal of Cancer</i> , 2021, , .	2.3	0
101	Radioresistance and genomic alterations in head and neck squamous cell cancer: Subâ€“analysis of the <scp>ProFiLER</scp> protocol. <i>Head and Neck</i> , 2021, 43, 3899-3910.	0.9	2
102	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. <i>European Journal of Cancer</i> , 2021, 158, 123-132.	1.3	11
103	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021, 21, 1180.	1.1	9
104	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 â€œCREATEâ€“ Trial. <i>Cancers</i> , 2021, 13, 6057.	1.7	9
105	Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome. <i>Scientific Reports</i> , 2021, 11, 23429.	1.6	1
106	Results of APIâ€“AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcomeâ€“09 study. <i>International Journal of Cancer</i> , 2020, 146, 413-423.	2.3	18
107	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	2.0	25
108	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020, 38, 831-843.	1.2	71

#	ARTICLE	IF	CITATIONS
109	Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors. CardioVascular and Interventional Radiology, 2020, 43, 110-119.	0.9	19
110	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncology, 2020, 16, 4251-4264.	1.1	43
111	The immune landscape of chondrosarcoma - potential for therapeutic targeting of CSFR1+ macrophages. Journal of Bone Oncology, 2020, 20, 100271.	1.0	23
112	Qualitative, Exploratory, and Multidimensional Study of Telepresence Robots for Overcoming Social Isolation of Children and Adolescents Hospitalized in Onco-Hematology. Journal of Adolescent and Young Adult Oncology, 2020, 9, 90-95.	0.7	7
113	A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. European Journal of Cancer, 2020, 125, 58-68.	1.3	23
114	Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. Annals of Surgical Oncology, 2020, 27, 1693-1699.	0.7	10
115	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. Oncologist, 2020, 25, e1-e4.	1.9	9
116	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6
117	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. ESMO Open, 2020, 5, e000787.	2.0	22
118	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Annals of Oncology, 2020, 31, 1506-1517.	0.6	103
119	Risk of death of patients with cancer presenting with severe symptoms of infection, with or without documented COVID-19: In reply to van Dam etAal.. European Journal of Cancer, 2020, 139, 68-69.	1.3	0
120	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapyâ€”A Multicenter Study by the French Sarcoma Group. American Journal of Roentgenology, 2020, 215, 1539-1548.	1.0	21
121	Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfilER 01 trial. Translational Oncology, 2020, 13, 100870.	1.7	8
122	Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocyoma. ESMO Open, 2020, 5, e000756.	2.0	5
123	Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open, 2020, 5, e001082.	2.0	2
124	Editorial: New Insights Into the Landscape of Rare Tumors: Translational and Clinical Research Perspective. Frontiers in Oncology, 2020, 10, 593785.	1.3	0
125	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. Cancers, 2020, 12, 3647.	1.7	3
126	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. European Journal of Cancer, 2020, 141, 162-170.	1.3	29

#	ARTICLE	IF	CITATIONS
127	Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways. <i>Cell Death Discovery</i> , 2020, 6, 64.	2.0	6
128	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. <i>Cancer</i> , 2020, 126, 4917-4925.	2.0	21
129	Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer. <i>Annals of Oncology</i> , 2020, 31, 1773-1775.	0.6	12
130	538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSÄ© basket trial. <i>Annals of Oncology</i> , 2020, 31, S470-S471.	0.6	1
131	Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. <i>Oncolmmunology</i> , 2020, 9, 1792036.	2.1	31
132	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	3.2	23
133	Ripretinib for advanced gastrointestinal stromal tumours – Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e415.	5.1	4
134	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1366-1377.	5.1	266
135	Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History. <i>Cancers</i> , 2020, 12, 2604.	1.7	22
136	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 957-963.	1.1	8
137	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020, 25, e1428-e1432.	1.9	3
138	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , 2020, 12, 3746.	1.7	6
139	1622MO Clinical benefit with ripretinib as 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study. <i>Annals of Oncology</i> , 2020, 31, S973-S974.	0.6	1
140	1636P METASYN: Patterns of care and outcomes of 387 METAstatic SYNovial sarcoma: Real-life data from the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , 2020, 31, S980.	0.6	0
141	1650P Desmoid type fibromatosis in patients. <i>Annals of Oncology</i> , 2020, 31, S985.	0.6	0
142	LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. <i>Annals of Oncology</i> , 2020, 31, S1199.	0.6	10
143	Pregnancy in Women with Metastatic Sarcomas. <i>Oncologist</i> , 2020, 25, e2010-e2012.	1.9	2
144	Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. <i>Annals of Oncology</i> , 2020, 31, 1087-1088.	0.6	96

#	ARTICLE	IF	CITATIONS
145	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISC), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	0.8	145
146	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). <i>PLoS ONE</i> , 2020, 15, e0233046.	1.1	8
147	Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. <i>Annals of Oncology</i> , 2020, 31, 822-823.	0.6	24
148	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 "CaboGIST". <i>European Journal of Cancer</i> , 2020, 134, 62-74.	1.3	42
149	Foreword. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1-2.	1.1	1
150	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. <i>Science</i> , 2020, 368, 1127-1131.	6.0	83
151	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 923-934.	5.1	224
152	Cabozantinib as an emerging treatment for sarcoma. <i>Current Opinion in Oncology</i> , 2020, 32, 321-331.	1.1	14
153	High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. <i>European Journal of Cancer</i> , 2020, 135, 251-259.	1.3	102
154	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020, 122, 1158-1165.	2.9	17
155	PTPN11 mutations in canine and human disseminated histiocytic sarcoma. <i>International Journal of Cancer</i> , 2020, 147, 1657-1665.	2.3	14
156	Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1807-1818.	1.1	14
157	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	2.2	29
158	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	2.0	86
159	Tumor Molecular Profiling: Pediatric Results of the ProFiLER Study. <i>JCO Precision Oncology</i> , 2020, 4, 785-795.	1.5	3
160	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
161	Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020, 10, 657-663.	7.7	93
162	Letter: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. <i>Neurosurgery</i> , 2020, 86, E480-E482.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 446-455.	5.1	182
164	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. <i>JAMA Oncology</i> , 2020, 6, 535.	3.4	33
165	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020, 86, 101993.	3.4	61
166	Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). <i>BMC Cancer</i> , 2020, 20, 117.	1.1	12
167	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020, 21, 456-466.	5.1	51
168	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020, 126, 45-55.	1.3	9
169	Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. <i>Annals of Oncology</i> , 2020, 31, 289-294.	0.6	105
170	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 1818-1827.	0.7	28
171	The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 29-39.	1.1	10
172	Clinical management of adolescents and young adults suffering from sarcoma in the French Rh�ne-Alpes region: A prospective exhaustive cohort with 10 years follow up. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1301-1309.	0.5	5
173	Overview of Â« druggable Â» alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 150, 102960.	2.0	1
174	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. <i>Oncolmmunology</i> , 2020, 9, 1747340.	2.1	101
175	French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. <i>Annals of Oncology</i> , 2020, 31, 965-966.	0.6	24
176	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , 2020, 11, 598118.	1.1	18
177	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	1.3	243
178	SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 607-616.	2.1	37
179	SRF Fusions Other Than With RELA Expand the Molecular Definition of SRF-fused Perivascular Tumors. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1725-1735.	2.1	14
180	First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. <i>ESMO Open</i> , 2020, 5, e001075.	2.0	14

#	ARTICLE	IF	CITATIONS
181	Beyond the map: evidencing the spatial dimension of health inequalities. <i>International Journal of Health Geographics</i> , 2020, 19, 46.	1.2	28
182	Quality of life (QoL) and self-reported function with ripretinib in 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11535-11535.	0.8	8
183	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in 4th-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11539-11539.	0.8	3
184	Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2020, 11, 1618-1628.	0.8	18
185	Title is missing!. , 2020, 15, e0233046.		0
186	Title is missing!. , 2020, 15, e0233046.		0
187	Title is missing!. , 2020, 15, e0233046.		0
188	Title is missing!. , 2020, 15, e0233046.		0
189	Title is missing!. , 2020, 15, e0233046.		0
190	Title is missing!. , 2020, 15, e0233046.		0
191	Networking in rare cancers: What was done, what's next. <i>European Journal of Surgical Oncology</i> , 2019, 45, 16-18.	0.5	23
192	ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based caseâ€“control studyâ€“study protocol. <i>BMJ Open</i> , 2019, 9, e030013.	0.8	8
193	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019, 19, 794.	1.1	20
194	Efficacy of Vemurafenib in Patients With Nonâ€“Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31
195	Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2019, 51, 1223-1231.	0.4	49
196	Pazopanib or methotrexateâ€“vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1263-1272.	5.1	123
197	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1252-1262.	5.1	57
198	Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. <i>Health Policy</i> , 2019, 123, 1230-1236.	1.4	17

#	ARTICLE	IF	CITATIONS
199	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. <i>European Journal of Cancer</i> , 2019, 118, 156-165.	1.3	11
200	Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. <i>Annals of Surgical Oncology</i> , 2019, 26, 3526-3534.	0.7	48
201	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019, 32, 1772-1785.	2.9	61
202	Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas. <i>Cancers</i> , 2019, 11, 922.	1.7	13
203	A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. <i>Annals of Oncology</i> , 2019, 30, v159.	0.6	13
204	Circulating tumour DNA (ctDNA) analysis depicts mechanisms of resistance and tumour response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2019, 30, v641.	0.6	2
205	CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts). <i>Annals of Oncology</i> , 2019, 30, v683.	0.6	6
206	Improved survival with secondary surgery in a reference center after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: An analysis 10931 patients (pts) in NETSARC. <i>Annals of Oncology</i> , 2019, 30, v686.	0.6	0
207	Impact of abstention of diagnostic biopsy in sarcoma. <i>Annals of Oncology</i> , 2019, 30, v686.	0.6	0
208	Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups. <i>Annals of Oncology</i> , 2019, 30, v686-v687.	0.6	0
209	Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts). <i>Annals of Oncology</i> , 2019, 30, v695.	0.6	0
210	The immune landscape of chondrosarcoma reveals an anti inflammatory environment. <i>Annals of Oncology</i> , 2019, 30, v700.	0.6	0
211	The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history. <i>Annals of Oncology</i> , 2019, 30, v702-v703.	0.6	0
212	EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT). <i>Annals of Oncology</i> , 2019, 30, v707.	0.6	1
213	National clinical-biological prospective cohort of incident cases of aggressive fibromatosis, AF (ALTITUDES). <i>Annals of Oncology</i> , 2019, 30, v709.	0.6	0
214	Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with locally advanced (LA) or metastatic relapsed chondrosarcoma (CS), on behalf of the French Sarcoma Group (FSG) and UNICANCER. <i>Annals of Oncology</i> , 2019, 30, v926-v927.	0.6	1
215	Outcome of 98 patients with epithelioid sarcoma treated in curative intent: A retrospective study from the French Sarcoma Group (GSF-GETO). <i>Annals of Oncology</i> , 2019, 30, v693.	0.6	1
216	INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). <i>Annals of Oncology</i> , 2019, 30, v925-v926.	0.6	11

#	ARTICLE	IF	CITATIONS
217	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019, 9, 14551.	1.6	41
218	New cytotoxic and target therapies for soft tissue sarcoma. <i>Annals of Oncology</i> , 2019, 30, vi44.	0.6	0
219	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 1719-1729.	5.1	143
220	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019, 119, 151-157.	1.3	103
221	Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation. <i>Annals of Oncology</i> , 2019, 30, 2008-2009.	0.6	15
222	Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?. <i>Future Oncology</i> , 2019, 15, 5-10.	1.1	6
223	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019, 11, 817.	1.7	11
224	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet</i> , The, 2019, 394, 478-487.	6.3	273
225	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	3.2	70
226	Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)â€”review and perspectives. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 24-24.	1.5	34
227	PARP1 expression in soft tissue sarcomas is a poorâ€”prognosis factor and a new potential therapeutic target. <i>Molecular Oncology</i> , 2019, 13, 1577-1588.	2.1	15
228	Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. <i>Annals of Oncology</i> , 2019, 30, 1401-1403.	0.6	72
229	Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. <i>Annals of Oncology</i> , 2019, 30, 1381-1392.	0.6	120
230	Personalised management of alveolar soft part sarcoma: a promising phase 2 study. <i>Lancet Oncology</i> , The, 2019, 20, 750-752.	5.1	2
231	Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e721-e723.	0.9	7
232	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019, 120, 1026-1032.	2.9	33
233	Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. <i>Annals of Surgical Oncology</i> , 2019, 26, 2286-2293.	0.7	87
234	International Collaborations and Regional Challenges in Providing Specialist Multidisciplinary Sarcoma Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 616-623.	1.8	9

#	ARTICLE	IF	CITATIONS
235	Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. <i>Surgical Oncology</i> , 2019, 29, 107-112.	0.8	46
236	Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EclinicalMedicine</i> , 2019, 9, 35-43.	3.2	49
237	Very long-term survivors among patients with metastatic soft tissue sarcoma. <i>Cancer Medicine</i> , 2019, 8, 1368-1378.	1.3	16
238	Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfILER trial. <i>Annals of Oncology</i> , 2019, 30, 757-765.	0.6	129
239	Surgery in reference centers improves survival of sarcoma patients: a nationwide study. <i>Annals of Oncology</i> , 2019, 30, 1143-1153.	0.6	191
240	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 4611-4615.	3.2	13
241	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. , 2019, 7, 85.		175
242	Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 691-698.	1.2	27
243	Sarcomas in patients over 90: Natural history and treatment – A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019, 145, 2135-2143.	2.3	10
244	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	3.2	80
245	Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019, 25, 1479-1485.	3.2	63
246	Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis. <i>Oncologist</i> , 2019, 24, e559-e564.	1.9	5
247	Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. <i>Oncologist</i> , 2019, 24, 980-988.	1.9	11
248	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. <i>EBioMedicine</i> , 2019, 48, 191-202.	2.7	55
249	Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers. <i>Annals of Oncology</i> , 2019, 30, vii23.	0.6	0
250	Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort. <i>Annals of Oncology</i> , 2019, 30, vii24.	0.6	1
251	MA12.01 Redefining Malignant Pleural Mesothelioma Types as a Continuum Uncovers Immune-Vascular Interactions. <i>Journal of Thoracic Oncology</i> , 2019, 14, S295.	0.5	1
252	Editorial: Customizing sarcoma management and treatment. <i>Current Opinion in Oncology</i> , 2019, 31, 302-303.	1.1	0

#	ARTICLE	IF	CITATIONS
253	Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nature Medicine, 2019, 25, 1519-1525.	15.2	332
254	SMARCA4-deficient Thoracic Sarcomas. American Journal of Surgical Pathology, 2019, 43, 455-465.	2.1	123
255	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 134-144.	5.1	97
256	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncology, The, 2019, 20, 120-133.	5.1	222
257	Patterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas. International Journal of Radiation Oncology Biology Physics, 2019, 103, 449-452.	0.4	7
258	RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas. Cancers, 2019, 11, 81.	1.7	3
259	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).. Journal of Clinical Oncology, 2019, 37, 11000-11000.	0.8	4
260	Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.. Journal of Clinical Oncology, 2019, 37, TPS5086-TPS5086.	0.8	5
261	A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.. Journal of Clinical Oncology, 2019, 37, TPS328-TPS328.	0.8	0
262	Proof-of-concept study evaluating a new tool for standardizing radiological assessment of tumor response to treatment in routine clinical practice.. Journal of Clinical Oncology, 2019, 37, e18079-e18079.	0.8	0
263	From rare to well-done: importance of rare tumors in cancer therapeutic advances. Oncotarget, 2019, 10, 3998-3999.	0.8	0
264	Abstract CT009: A Phase Ib study assessing biomarker modulation in soft tissue sarcoma patients treated with olaratumab followed by olaratumab plus doxorubicin. , 2019, , .		0
265	Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study. Blood, 2019, 134, 5817-5817.	0.6	1
266	Radiomics improves response evaluation for desmoid tumours treated with chemotherapy. Annals of Oncology, 2019, 30, v699.	0.6	0
267	Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1094-1100.	0.6	9
268	A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. Personalized Medicine, 2018, 15, 13-24.	0.8	0
269	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 1304 trial). Lancet Respiratory Medicine, 2018, 6, 431-441.	0.784314	134
270	Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. Nature Reviews Clinical Oncology, 2018, 15, 443-458.	12.5	56

#	ARTICLE	IF	CITATIONS
271	Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene. <i>Annals of Oncology</i> , 2018, 29, 1488-1489.	0.6	21
272	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
273	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-ESTBSG). <i>International Journal of Cancer</i> , 2018, 142, 2610-2620.	2.3	32
274	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 â€˜CREATEâ€™. <i>Annals of Oncology</i> , 2018, 29, 758-765.	0.6	67
275	European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. <i>Clinical Oncology</i> , 2018, 30, 448-454.	0.6	29
276	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 639-648.	5.1	81
277	Gastrointestinal stromal tumors (GIST) presenting in the liver: Diagnostic, prognostic and therapeutic issues. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, e23-e28.	0.7	12
278	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas. <i>JAMA Oncology</i> , 2018, 4, 93.	3.4	303
279	The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. <i>Annals of Oncology</i> , 2018, 29, 459-465.	0.6	24
280	Vemurafenib for <i>BRAF</i> V600E-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	3.4	280
281	Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. <i>Cancer</i> , 2018, 124, 1179-1187.	2.0	47
282	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018, 23, 461-467.	1.9	27
283	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	1.9	62
284	A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950). <i>Annals of Oncology</i> , 2018, 29, viii580-viii581.	0.6	12
285	Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST. <i>Annals of Oncology</i> , 2018, 29, viii582.	0.6	0
286	BRAF Inhibition in <i>BRAF</i> ^{V600E} -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	0.8	247
287	Proof-of-concept study evaluating a new tool for standardising radiological assessment of tumour response to treatment in routine clinical practice. <i>Annals of Oncology</i> , 2018, 29, viii482.	0.6	0
288	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3324-3330.	0.8	61

#	ARTICLE	IF	CITATIONS
289	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018, 36, 3110-3119.	0.8	107
290	OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSÂ© Trial.. <i>Journal of Thoracic Oncology</i> , 2018, 13, S348-S349.	0.5	11
291	Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients. <i>Annals of Oncology</i> , 2018, 29, viii579.	0.6	0
292	mTOR inhibitors in uterine and extra-uterine malignant PEComas: A multicenter international case series retrospective analysis. <i>Annals of Oncology</i> , 2018, 29, viii581.	0.6	2
293	Correlation between an automated functional assay that predicts targeted agent (TA) sensitivity and the tumor response of the sorafenib treatment evaluated within the MOST clinical trial. <i>Annals of Oncology</i> , 2018, 29, vi15-vi16.	0.6	0
294	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring <i>BRAF</i> ^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	20
295	Data-mining of 110 172 electronic patient records with the ConSoRe tool: An analysis of second primary cancer in a comprehensive cancer center. <i>Annals of Oncology</i> , 2018, 29, viii482.	0.6	1
296	A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors) Tj ETQq0 0 0 rgBT /Overlock,10 Tf 50 4	0.6	4
297	Geographical Accessibility of the Sarcoma Referral Networks in France. Intermediate Results from the IGÂ©AS Research Program. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2204.	1.2	20
298	Bone sarcomas: ESMOâ€œPaedCanâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv79-iv95.	0.6	380
299	EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. <i>PLoS ONE</i> , 2018, 13, e0204117.	1.1	9
300	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2018, 23, 948-955.	1.9	18
301	Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. <i>Oncogenesis</i> , 2018, 7, 74.	2.1	45
302	The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. <i>PLoS ONE</i> , 2018, 13, e0193330.	1.1	38
303	Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. <i>BMC Cancer</i> , 2018, 18, 963.	1.1	15
304	Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 399-406.	0.4	27
305	Gastrointestinal stromal tumours: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv68-iv78.	0.6	413
306	Soft tissue and visceral sarcomas: ESMOâ€œEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv51-iv67.	0.6	641

#	ARTICLE	IF	CITATIONS
307	Management of sarcoma patients: centralization in reference centers to fragmentation of systemic treatment. <i>Current Opinion in Oncology</i> , 2018, 30, 240-242.	1.1	5
308	Getting up-to-date in the management of soft tissue sarcoma. <i>Future Oncology</i> , 2018, 14, 3-13.	1.1	13
309	Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. <i>Modern Pathology</i> , 2018, 31, 1683-1693.	2.9	56
310	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018, 7, 4023-4035.	1.3	39
311	A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. <i>BMC Cancer</i> , 2018, 18, 646.	1.1	42
312	Joint adolescentâ€“adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platformâ€”ACCELERATE. <i>Annals of Oncology</i> , 2018, 29, 766-771.	0.6	63
313	Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. <i>Preventive Medicine Reports</i> , 2018, 10, 332-336.	0.8	4
314	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018, 99, 28-36.	1.3	13
315	Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma. <i>Cancer Research</i> , 2018, 78, CT009-CT009.	0.4	11
316	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018, 132, 391-391.	0.6	40
317	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11502-11502.	0.8	16
318	Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11504-11504.	0.8	6
319	Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11508-11508.	0.8	5
320	Survival impact of surgical management in reference centers for retroperitoneal sarcoma: A nationwide study of FSG-GETO and NETSARC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11568-11568.	0.8	5
321	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11574-11574.	0.8	6
322	Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5505-5505.	0.8	5
323	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 34617-34627.	0.8	9
324	Vnn1 pantetheinase limits the Warburg effect and sarcoma growth by rescuing mitochondrial activity. <i>Life Science Alliance</i> , 2018, 1, e201800073.	1.3	24

#	ARTICLE	IF	CITATIONS
325	Efficacy of antiangiogenic renal neoplasm with bone metastasis: A mono-institutional study in France.. Journal of Clinical Oncology, 2018, 36, 610-610.	0.8	0
326	The 100 Most Influential Papers and Recent Trends in the Field of Gastrointestinal Stromal Tumours: A Bibliometric Analysis. Cureus, 2018, 10, e2311.	0.2	4
327	Compared descriptive analysis of immunologic landscape in soft tissue sarcoma and GIST.. Journal of Clinical Oncology, 2018, 36, 11517-11517.	0.8	0
328	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 11540-11540.	0.8	1
329	PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.. Journal of Clinical Oncology, 2018, 36, TPS11587-TPS11587.	0.8	3
330	Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.. Journal of Clinical Oncology, 2018, 36, 11523-11523.	0.8	0
331	Characteristics and clinical outcomes of French patients diagnosed with advanced soft tissue sarcoma (aSTS) in real-life setting: Data from the European sarcoma biological and clinical data banking (ESBCB).. Journal of Clinical Oncology, 2018, 36, 11548-11548.	0.8	0
332	Sarcomas in patients over 90: Natural history and treatmentâ€”A nationwide study over 6 years.. Journal of Clinical Oncology, 2018, 36, 11564-11564.	0.8	0
333	Enjeux et difficultÃ©s de la gestion des mÃ©dicaments onÃ©ocgrÃ©s dans la liste en sus pour un hÃ©pital traitant des cancers. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1003-1012.	0.0	0
334	Abstract 1841: Integrative analysis of resistance to BRAF-targeted therapies in lung adenocarcinomas. , 2018, , .		0
335	Abstract CT045: Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE". Cancer Research, 2018, 78, CT045-CT045.	0.4	1
336	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. Oncolmmunology, 2017, 6, e1137418.	2.1	42
337	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncolmmunology, 2017, 6, e1278100.	2.1	65
338	3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma. EJNMMI Physics, 2017, 4, 6.	1.3	14
339	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. Aâ€”retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression FranÃ§aise (ANOCEF). European Journal of Cancer, 2017, 79, 119-128.	1.3	45
340	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	5.1	370
341	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Medicine, 2017, 15, 78.	2.3	143
342	Intensity of recent years in the investigation of soft tissue sarcoma. Future Oncology, 2017, 13, 3-9.	1.1	3

#	ARTICLE	IF	CITATIONS
343	Review of past and present clinical cases with a view to future treatment options. <i>Future Oncology</i> , 2017, 13, 11-28.	1.1	4
344	Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG). <i>European Journal of Surgical Oncology</i> , 2017, 43, 1110-1116.	0.5	10
345	Giant cell tumour of bone in the denosumab era. <i>European Journal of Cancer</i> , 2017, 77, 75-83.	1.3	117
346	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017, 28, 1230-1242.	0.6	168
347	P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSÂ© Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1182-S1183.	0.5	2
348	P1.01-010 Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians. <i>Journal of Thoracic Oncology</i> , 2017, 12, S453-S454.	0.5	0
349	P1.03-040 Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey. <i>Journal of Thoracic Oncology</i> , 2017, 12, S566-S567.	0.5	0
350	Description of the immune microenvironment of chondrosarcoma and contribution to progression. <i>Oncolmmunology</i> , 2017, 6, e1265716.	2.1	26
351	Sarcoma in irradiated area (SARI): radiation-induced CD8 T-lymphocytes apoptosis as a potential predisposition factor: results of the SARI trial. <i>European Journal of Cancer</i> , 2017, 72, S153-S154.	1.3	0
352	Subgroup analysis of leiomyosarcoma patients from a phase 3, open-label, randomized study of eribulin versus dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>European Journal of Cancer</i> , 2017, 72, S155.	1.3	0
353	Improving treatment results with reference centres forÂ rare cancers: where do we stand?. <i>European Journal of Cancer</i> , 2017, 77, 90-98.	1.3	44
354	<scp>REGOSARC</scp>: Regorafenib versus placebo in doxorubicinâ€refractory softâ€tissue sarcomaâ€A qualityâ€adjusted time without symptoms of progression or toxicity analysis. <i>Cancer</i> , 2017, 123, 2294-2302.	2.0	38
355	Evolution in soft tissue sarcoma. <i>Future Oncology</i> , 2017, 13, 1-2.	1.1	6
356	Advances and controversies in the management of soft tissue sarcomas. <i>Future Oncology</i> , 2017, 13, 3-11.	1.1	8
357	Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. <i>European Journal of Cancer</i> , 2017, 72, 12-19.	1.3	14
358	Evolving biological understanding and treatment of sarcomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 78-80.	12.5	12
359	Actionable molecular alterations in advanced gynecologic malignancies: updated results from the ProfilER program in France. <i>Annals of Oncology</i> , 2017, 28, vii14.	0.6	0
360	Genomic Alterations and Radioresistance in Breast Cancer: An Analysis of the Profiler Protocol. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S52.	0.4	2

#	ARTICLE	IF	CITATIONS
361	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 â€œCREATEâ€™. <i>Annals of Oncology</i> , 2017, 28, 3000-3008.	0.6	70
362	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017, 117, 1278-1285.	2.9	33
363	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017, 83, 125-131.	1.3	134
364	<i>MDM4</i> amplification in a case of dedifferentiated liposarcoma and <i>in silico</i> data supporting an oncogenic event alternative to <i>MDM2</i> amplification in a subset of cases. <i>Histopathology</i> , 2017, 71, 1019-1023.	1.6	13
365	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSC). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	0.6	274
366	Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. <i>Annals of Oncology</i> , 2017, 28, 1779-1787.	0.6	104
367	Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). <i>BMC Cancer</i> , 2017, 17, 111.	1.1	11
368	Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study. <i>BMC Cancer</i> , 2017, 17, 419.	1.1	3
369	Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTCâ€™s). <i>Clinical Sarcoma Research</i> , 2017, 7, 10.	2.3	15
370	Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Drug Investigation</i> , 2017, 37, 85-94.	1.1	3
371	European Journal of Cancerâ€™s Biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas. <i>European Journal of Cancer</i> , 2017, 70, 83-86.	1.3	5
372	Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METastatic Soft Tissue SARcoma (STS) in a Real-Life Setting: an ancillary analysis of the METASARC Study. <i>Annals of Oncology</i> , 2017, 28, v531.	0.6	0
373	Genomic alterations and radioresistance in breast cancer: an analysis of the ProfILER protocol. <i>Annals of Oncology</i> , 2017, 28, 2773-2779.	0.6	23
374	A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide and cisplatin (API), followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). Update at 10 years. <i>Annals of Oncology</i> , 2017, 28, v521-v522.	0.6	0
375	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , 2017, 7, 17917.	1.6	10
376	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 1787-1797.	2.9	30
377	Adult Translocation-related soft tissue sarcomas (TRS): Presentation, management and outcome of 2,143 cases confirmed by expert pathologists. <i>Annals of Oncology</i> , 2017, 28, v522.	0.6	1
378	EORTC experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: Clinical profile and response to systemic therapy. <i>Annals of Oncology</i> , 2017, 28, v528.	0.6	1

#	ARTICLE	IF	CITATIONS
379	Actionable molecular alterations in advanced gynecologic malignancies: First results from the ProfiLER program (NCT01774409) in France. <i>Annals of Oncology</i> , 2017, 28, v333.	0.6	1
380	Recommended cancer screening and vulnerable populations: results from the EDIFICE 5 survey. <i>Annals of Oncology</i> , 2017, 28, v506.	0.6	0
381	Fluctuating cancer screening uptake in France: results of the 5th EDIFICE survey. <i>Annals of Oncology</i> , 2017, 28, v502.	0.6	0
382	Analysis of compliance factors for colorectal cancer screening using a Bayesian network. <i>Annals of Oncology</i> , 2017, 28, v512.	0.6	0
383	Improved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC. <i>Annals of Oncology</i> , 2017, 28, v521.	0.6	5
384	PROFILER 02 - A multicentric, prospective cohort study aiming to evaluate the added value of a large molecular profiling panel (315 cancer-related gene panel [FoundationOne]) versus a limited molecular profiling panel (74 cancer-related gene panel [CONTROL]) in advanced solid tumours. <i>Annals of Oncology</i> , 2017, 28, vii4.	0.6	1
385	Actionable molecular alterations in advanced biliary tract carcinomas: Preliminary data from the ProfiLER program (NCT01774409). <i>Annals of Oncology</i> , 2017, 28, v247.	0.6	0
386	Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study. <i>Annals of Oncology</i> , 2017, 28, v645-v646.	0.6	3
387	Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?. <i>PLoS ONE</i> , 2017, 12, e0171639.	1.1	45
388	Efficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib. <i>Annals of Oncology</i> , 2017, 28, v523-v524.	0.6	0
389	Improved survival using specialized multidisciplinary board in sarcoma patients. <i>Annals of Oncology</i> , 2017, 28, 2852-2859.	0.6	255
390	Natural history of alveolar soft part sarcoma (ASPS): Impact of brain metastases and role of anti-angiogenic therapies (AAT). <i>Annals of Oncology</i> , 2017, 28, v526.	0.6	0
391	Cervical cancer screening in France: recent change in behaviors. <i>Annals of Oncology</i> , 2017, 28, v504.	0.6	0
392	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	0.8	148
393	A new chemotherapy-based combination to prevent osteosarcoma progression. <i>Annals of Oncology</i> , 2017, 28, v588.	0.6	0
394	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3433-3439.	0.8	126
395	Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11003-11003.	0.8	3
396	Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11053-11053.	0.8	9

#	ARTICLE	IF	CITATIONS
397	Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase I/II trial—A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) groups study.. Journal of Clinical Oncology, 2017, 35, 11061-11061.	0.8	3
398	International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.. Journal of Clinical Oncology, 2017, 35, 11062-11062.	0.8	3
399	A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).. Journal of Clinical Oncology, 2017, 35, 11078-11078.	0.8	26
400	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology, 2017, 35, 2004-2004.	0.8	1
401	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i> V600 mutation.. Journal of Clinical Oncology, 2017, 35, 9074-9074.	0.8	10
402	Undifferentiated endometrial sarcomas (UES): Results of a French sarcoma group (FSG) retrospective series of 52 patients (pts).. Journal of Clinical Oncology, 2017, 35, e17109-e17109.	0.8	2
403	Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the Profiler Study.. Journal of Clinical Oncology, 2017, 35, LBA100-LBA100.	0.8	6
404	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in <i>PDGFRA</i> : The CrenoGIST study.. Journal of Clinical Oncology, 2017, 35, TPS11080-TPS11080.	0.8	11
405	Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the Profiler study.. Journal of Clinical Oncology, 2017, 35, LBA100-LBA100.	0.8	13
406	Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.1	67
407	Pigmented villonodular synovitis: Opening options in management. Drugs of the Future, 2017, 42, 0105.	0.0	0
408	Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians.. Journal of Clinical Oncology, 2017, 35, 536-536.	0.8	1
409	Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.. Journal of Clinical Oncology, 2017, 35, 11052-11052.	0.8	2
410	SYNFRIZZ: A first-in-human (FIH) study of a radiolabeled monoclonal antibody (Mab) targeting frizzled homolog 10 (FZD10) in patients (pts) with advanced synovial sarcomas (SyS).. Journal of Clinical Oncology, 2017, 35, 11054-11054.	0.8	1
411	Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts).. Journal of Clinical Oncology, 2017, 35, 11047-11047.	0.8	0
412	Expression and prognostic significance of PDGF ligands (A, B, C, and D) and PDGFR (A, B, and L) in soft-tissue sarcomas and GIST.. Journal of Clinical Oncology, 2017, 35, 11067-11067.	0.8	0
413	Weekly paclitaxel (WP) +/- bevacizumab (B) in angiosarcoma (AS) patients (pts): Analysis of prognostic/predictive factors from a randomized phase 2 trial.. Journal of Clinical Oncology, 2017, 35, 11024-11024.	0.8	0
414	Long-term survival (over 10 years) of inoperable/metastatic GISTs: A retrospective series of 141 patients (pts) of the french sarcoma group (FSG).. Journal of Clinical Oncology, 2017, 35, 11041-11041.	0.8	0

#	ARTICLE	IF	CITATIONS
415	Outcome of 212 malignant phyllod tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO).. Journal of Clinical Oncology, 2017, 35, 11055-11055.	0.8	0
416	A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.. Journal of Clinical Oncology, 2017, 35, e14627-e14627.	0.8	0
417	Abstract LB-190: Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study. Cancer Research, 2017, 77, LB-190-LB-190.	0.4	1
418	Patients with primary localized high-grade sarcomas of the digestive tract excluding GIST : a retrospective study from the French sarcoma group. Acta Gastro-Enterologica Belgica, 2017, 80, 481-486.	0.4	1
419	Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts). Annals of Oncology, 2016, 27, vii74.	0.6	1
420	Regorafenib (R) versus placebo (P) in soft tissue sarcomas (STS): analysis of genetic prognostic and predictive factors. Annals of Oncology, 2016, 27, vi486.	0.6	1
421	Cervical cancer: Awareness and misconceptions of risk factors among lay persons and physicians. Annals of Oncology, 2016, 27, vi306.	0.6	1
422	Personalized medicine for advanced pancreas cancer: access to treatment according to molecular profile. Annals of Oncology, 2016, 27, vi225.	0.6	0
423	Lower risk of cutaneous squamous cell carcinomas induced by vemurafenib in non melanoma patients. Annals of Oncology, 2016, 27, vi391.	0.6	0
424	Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO). Annals of Oncology, 2016, 27, vi486.	0.6	1
425	Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. European Journal of Cancer Care, 2016, 25, 466-477.	0.7	5
426	Adjuvant imatinib treatment in gastrointestinal stromal tumor. Anti-Cancer Drugs, 2016, 27, 71-75.	0.7	8
427	Current or former smokers: Who wants to be screened?. Annals of Oncology, 2016, 27, vi478.	0.6	0
428	A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. European Journal of Cancer, 2016, 69, S34.	1.3	3
429	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncology, The, 2016, 17, 632-641.	5.1	98
430	Aggregated adverse-events outcomes in oncology phase III reports: A systematic review. European Journal of Cancer, 2016, 52, 26-32.	1.3	4
431	Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecologic Oncology, 2016, 142, 89-94.	0.6	54
432	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. Gynecologic Oncology, 2016, 142, 95-101.	0.6	14

#	ARTICLE	IF	CITATIONS
433	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , 2016, 58, 90-96.	1.3	111
434	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016, 6, 15.	2.3	80
435	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology</i> , The, 2016, 17, 1261-1271.	5.1	161
436	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016, 23, 3531-3540.	0.7	136
437	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3898-3905.	0.8	151
438	The emerging role of ATRX and chromatin remodeling in pleomorphic sarcomas oncogenesis. <i>European Journal of Cancer</i> , 2016, 61, S28.	1.3	1
439	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1732-1742.	5.1	200
440	The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment. <i>Annals of Oncology</i> , 2016, 27, vi483.	0.6	7
441	Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial. <i>Annals of Oncology</i> , 2016, 27, vi16.	0.6	1
442	Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMS. <i>Annals of Oncology</i> , 2016, 27, vi485.	0.6	1
443	sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. <i>Annals of Oncology</i> , 2016, 27, vi587.	0.6	17
444	Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS). <i>Annals of Oncology</i> , 2016, 27, vi483.	0.6	4
445	Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS). <i>Annals of Oncology</i> , 2016, 27, vi486.	0.6	3
446	Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): updated safety data of the phase 3 GRID trial. <i>Annals of Oncology</i> , 2016, 27, vi489.	0.6	1
447	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1070-1080.	5.1	170
448	Equal access to innovative therapies and precision cancer care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 385-393.	12.5	43
449	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet</i> , The, 2016, 387, 1629-1637.	6.3	610
450	Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2016, 52, 173-180.	1.3	68

#	ARTICLE	IF	CITATIONS
451	The value of research collaborations and consortia in rare cancers. <i>Lancet Oncology</i> , The, 2016, 17, e62-e69.	5.1	89
452	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016, 16, 22.	1.1	52
453	Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. <i>European Journal of Cancer</i> , 2016, 57, 31-38.	1.3	71
454	The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. <i>Annals of Oncology</i> , 2016, 27, 192-198.	0.6	23
455	Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Report of a Bilateral Case in a Teenager Associated with <i>SMARCA4</i> Germline Mutation. <i>Pediatric and Developmental Pathology</i> , 2016, 19, 56-60.	0.5	15
456	Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. <i>Journal of Gastroenterology</i> , 2016, 51, 571-578.	2.3	50
457	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. <i>Gastric Cancer</i> , 2016, 19, 3-14.	2.7	339
458	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016, 128, 480-480.	0.6	5
459	Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 11003-11003.	0.8	4
460	Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity. <i>Journal of Clinical Oncology</i> , 2016, 34, 11008-11008.	0.8	11
461	Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014. <i>Journal of Clinical Oncology</i> , 2016, 34, 11013-11013.	0.8	10
462	Patterns of care and outcome of patients (pts) with metastatic soft-tissue sarcoma (STS) according to histological subtype and treatment setting: The METASTAR study. <i>Journal of Clinical Oncology</i> , 2016, 34, 11014-11014.	0.8	4
463	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). <i>Journal of Clinical Oncology</i> , 2016, 34, 11037-11037.	0.8	5
464	Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST). <i>Journal of Clinical Oncology</i> , 2016, 34, 156-156.	0.8	9
465	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , 2016, 7, 73984-73994.	0.8	23
466	Abstract P6-09-14: Awareness of breast cancer risk factors among lay persons and physicians. , 2016, , .		0
467	Ewing sarcoma Family of Tumors in Older Patients (EFyTOP): Management and outcome of Ewing sarcoma family of tumors (EFTs) in patients older than 50 years. <i>Journal of Clinical Oncology</i> , 2016, 34, 11023-11023.	0.8	0
468	First things first: Prevention, screening or care?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1550-1550.	0.8	0

#	ARTICLE	IF	CITATIONS
469	Molecular targeted therapies (MTT) in advanced chordoma (AC) patients (pts).. Journal of Clinical Oncology, 2016, 34, 11020-11020.	0.8	1
470	Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSÂ© Program.. Journal of Clinical Oncology, 2016, 34, TPS11620-TPS11620.	0.8	1
471	Abstract 2338: CD39+ Treg cooperate with a CD73-expressing Th1/Th17 subset for Adenosine-mediated immunosuppression in human breast tumors. , 2016, , .		0
472	Impact of the Use of Polymerase Chain Reaction for the Diagnosis and Management of Pneumocystis Jirovecii Pneumoniae in a Retrospective Cohort of Patients with Lymphoid Malignancies. Blood, 2016, 128, 688-688.	0.6	0
473	12LBA Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSe Program. European Journal of Cancer, 2015, 51, S715.	1.3	3
474	1208 Being cured: What it means and what it takes. European Journal of Cancer, 2015, 51, S174.	1.3	0
475	3441 Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: Health-related quality of life results. European Journal of Cancer, 2015, 51, S702.	1.3	0
476	Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial. European Journal of Cancer, 2015, 51, 2453-2464.	1.3	21
477	Detection of tumor <i><sc>ALK</sc></i> status in neuroblastoma patients using peripheral blood. Cancer Medicine, 2015, 4, 540-550.	1.3	65
478	Prediction of desmoid tumor progression using mi<sc>RNA</sc> expression profiling. Cancer Science, 2015, 106, 650-655.	1.7	12
479	1101 Less cancer screening in the vulnerable population? Results from the EDIFICE 4 survey. European Journal of Cancer, 2015, 51, S164.	1.3	0
480	31LBA MOST â€“ My Own Specific Therapy â€“ A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. European Journal of Cancer, 2015, 51, S725-S726.	1.3	0
481	Targeting tumor-associated macrophages in cancer patients. Annals of Oncology, 2015, 26, ii12.	0.6	0
482	Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTCâ€™S (Observatoire de lâ€™Utilisation des ThÃ©rapies CiblÃ©es dans les Sarcomes). BMC Cancer, 2015, 15, 854.	1.1	25
483	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer, 2015, 15, 700.	1.1	37
484	KIT exon 10 variant (c.1621 Aâ€™%>â€™%C) single nucleotide polymorphism as predictor of GIST patient outcome. BMC Cancer, 2015, 15, 780.	1.1	13
485	Healthâ€™related qualityâ€™ofâ€™life results from PALETTE: A randomized, doubleâ€™blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapyâ€™a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (FORTC 62072). Cancer, 2015, 121, 2933-2941.	2.0	72
486	Primary cutaneous and subcutaneous Ewing sarcoma. Pediatric Blood and Cancer, 2015, 62, 1555-1561.	0.8	25

#	ARTICLE	IF	CITATIONS
487	Challenges in the implementation of trastuzumab biosimilars. <i>Anti-Cancer Drugs</i> , 2015, 26, 1009-1016.	0.7	12
488	Lung cancer risks, beliefs and healthcare access among the underprivileged. <i>European Journal of Cancer Prevention</i> , 2015, 24, S82-S86.	0.6	9
489	Cancer screening in France. <i>European Journal of Cancer Prevention</i> , 2015, 24, S68-S72.	0.6	9
490	Trabectedin in advanced synovial sarcomas. <i>Anti-Cancer Drugs</i> , 2015, 26, 678-681.	0.7	44
491	Breast cancer screening controversy. <i>European Journal of Cancer Prevention</i> , 2015, 24, S73-S76.	0.6	8
492	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncolmmunology</i> , 2015, 4, e998538.	2.1	119
493	Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. <i>Clinical Sarcoma Research</i> , 2015, 5, 12.	2.3	38
494	Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015, 51, 742-750.	1.3	86
495	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2015, 16, 312-319.	5.1	78
496	Treating metastatic sarcomas locally: A paradoxe, a rationale, an evidence?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 62-77.	2.0	18
497	An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID). <i>Annals of Oncology</i> , 2015, 26, v96.	0.6	0
498	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	0.8	148
499	Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. <i>Clinical Cancer Research</i> , 2015, 21, 4194-4200.	3.2	43
500	209 The sum of gains and losses of genes encoding for protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment. <i>European Journal of Cancer</i> , 2015, 51, S30.	1.3	0
501	Disequilibrium of BMP2 Levels in the Breast Stem Cell Niche Launches Epithelial Transformation by Overamplifying BMPR1B Cell Response. <i>Stem Cell Reports</i> , 2015, 4, 239-254.	2.3	54
502	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015, 51, 271-281.	1.3	108
503	Building a global consensus approach to chordoma: a position paper from the medical and patient community. <i>Lancet Oncology, The</i> , 2015, 16, e71-e83.	5.1	367
504	Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. <i>Oncology</i> , 2015, 89, 1-13.	0.9	24

#	ARTICLE	IF	CITATIONS
505	A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: The TRUSTS trial. <i>European Journal of Cancer</i> , 2015, 51, 1312-1320.	1.3	63
506	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015, 20, 823-830.	1.9	26
507	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015, 26, 300-306.	0.6	77
508	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 949-956.	5.1	298
509	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event) Tj ETQq1 1 0.784314.6BT / Overlock 10	1.6	10
510	Hemorrhage due to radiation-induced sarcoma of the mandible: Treatment with percutaneous cryotherapy. <i>Diagnostic and Interventional Imaging</i> , 2015, 96, 407-409.	1.8	0
511	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 550-560.	5.1	96
512	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 531-540.	5.1	56
513	Prostate cancer screening: contrasting trends. <i>Cancer Causes and Control</i> , 2015, 26, 949-952.	0.8	10
514	Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. <i>BMC Cancer</i> , 2015, 15, 127.	1.1	22
515	Giant cell tumors of bone. , 2015, , 437-445.		2
516	ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. <i>Annals of Oncology</i> , 2015, 26, 1353-1362.	0.6	63
517	Assessing the Multimodal Management of Advanced Solitary Fibrous Tumors of the Pleura in a Routine Practice Setting. <i>Journal of Thoracic Oncology</i> , 2015, 10, 309-315.	0.5	23
518	First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)â€”a systematic review and individual patient data meta-analysis. <i>Annals of Oncology</i> , 2015, 26, 1305-1313.	0.6	152
519	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2797-2802.	0.8	153
520	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , 2015, 26, 2168-2173.	0.6	93
521	1100 Limiting factors to appropriate follow-up in cervical cancer screening. <i>European Journal of Cancer</i> , 2015, 51, S164.	1.3	0
522	3400 Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc). <i>European Journal of Cancer</i> , 2015, 51, S688.	1.3	0

#	ARTICLE	IF	CITATIONS
523	Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v40-v55.	0.6	346
524	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	13.9	1,483
525	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. <i>Nature Genetics</i> , 2015, 47, 1200-1205.	9.4	252
526	Nilotinib versus imatinib for GIST – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e311-e312.	5.1	0
527	The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. <i>European Journal of Cancer</i> , 2015, 51, 2423-2433.	1.3	28
528	Etoposide and carboplatin combination therapy in refractory or relapsed Ewing sarcoma: A large retrospective study. <i>Pediatric Blood and Cancer</i> , 2015, 62, 40-44.	0.8	18
529	Social stratification, risk factor prevalence and cancer screening attendance. <i>European Journal of Cancer Prevention</i> , 2015, 24, S77-S81.	0.6	8
530	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015, 126, 4263-4263.	0.6	9
531	Cancer screening in France: Reaching a plateau? New edition of an iterative nationwide survey.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1565-1565.	0.8	2
532	Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3005-3005.	0.8	28
533	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA10502-LBA10502.	0.8	22
534	An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID).. <i>Journal of Clinical Oncology</i> , 2015, 33, 110-110.	0.8	7
535	Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 586-586.	0.8	2
536	Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients. <i>PLoS ONE</i> , 2015, 10, e0138386.	1.1	34
537	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 14139-14152.	0.8	22
538	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. <i>Oncotarget</i> , 2015, 6, 26388-26399.	0.8	9
539	Abstract PR04: Targeting tumor-associated macrophages with a novel anti-CSF1R antibody in cancer patients. , 2015, , .		0
540	Identification des voies de signalisations essentielles à la progression tumorale dans les sarcomes : un modèle pour les interactions cellules tumorales et stroma. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2015, 199, 41-61.	0.0	0

#	ARTICLE	IF	CITATIONS
541	A randomized, open-label, Phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors.. Journal of Clinical Oncology, 2015, 33, TPS2622-TPS2622.	0.8	1
542	Risk factors of pneumocytis pneumoniae in solid tumours: A case-control study. , 2015, , .		0
543	Abstract A14: Overcoming therapeutic MAb resistance in aggressive HER2 positive breast carcinomas by adoptive immunotherapy using optimized effectors cells. , 2015, , .		0
544	Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution. Blood, 2015, 126, 1544-1544.	0.6	2
545	Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region. International Journal of Clinical Oncology, 2014, 19, 744-52.	1.0	32
546	Breast Cancer Screening Controversy: Impact on Other Cancer Screening Programs. Annals of Oncology, 2014, 25, iv479.	0.6	0
547	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
548	Evolving Biology of Sarcoma. Annals of Oncology, 2014, 25, iv31.	0.6	0
549	Screening for Breast Cancer. Fear and Reassurance: Impact of the Recent Controversy. Annals of Oncology, 2014, 25, iv479.	0.6	0
550	Low Adequacy Between Severe Adverse Events Reporting in Oncology Phase III Trials and Expectations of the Eortc Members. Annals of Oncology, 2014, 25, iv487.	0.6	0
551	Zoledronate Does not Reduce the Risk of Treatment Failure in Osteosarcoma: Results of the French Multicentre Os2006 Randomised Trial. Annals of Oncology, 2014, 25, iv494.	0.6	5
552	Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii102-iii112.	0.6	432
553	Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. Future Oncology, 2014, 10, 59-68.	1.1	23
554	Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft tissue sarcoma patients in the competing risks setting. Cancer, 2014, 120, 3361-3369.	2.0	68
555	Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii21-iii26.	0.6	312
556	Optimizing Treatment Outcomes With Regorafenib: Personalized Dosing and Other Strategies to Support Patient Care. Oncologist, 2014, 19, 669-680.	1.9	61
557	The off-label use of targeted therapies in sarcomas: the OUTCOME™ program. BMC Cancer, 2014, 14, 870.	1.1	20
558	Dsh Homolog DVL3 Mediates Resistance to IGF1R Inhibition by Regulating IGF-RAS Signaling. Cancer Research, 2014, 74, 5866-5877.	0.4	23

#	ARTICLE	IF	CITATIONS
559	Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. <i>Annals of Oncology</i> , 2014, 25, 1762-1769.	0.6	65
560	Cost of Discordant Diagnoses in Sarcoma, Gist, and Desmoid Tumors in France: Results From the RREPS (Reseau De Reference En Pathologie Des Sarcomes) Network. <i>Value in Health</i> , 2014, 17, A95-A96.	0.1	4
561	Going further in the knowledge of Yondelis®; what's new in daily clinical practice?. <i>Future Oncology</i> , 2014, 10, s13-s17.	1.1	2
562	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study. <i>Cancer</i> , 2014, 120, 2448-2456.	2.0	158
563	Going further in the knowledge of Yondelis®; what's new in clinical trials?. <i>Future Oncology</i> , 2014, 10, s7-s12.	1.1	2
564	The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors. <i>Annals of Oncology</i> , 2014, 25, 1074-1075.	0.6	3
565	Long-term recurrence of soft tissue sarcomas: Prognostic factors and implications for prolonged follow-up. <i>Cancer</i> , 2014, 120, 3003-3006.	2.0	40
566	Response to chemotherapy is not related to chromosome instability in synovial sarcoma. <i>Annals of Oncology</i> , 2014, 25, 2267-2271.	0.6	29
567	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. <i>Annals of Oncology</i> , 2014, 25, 2425-2432.	0.6	135
568	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014, 20, 6105-6116.	3.2	129
569	Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. <i>BMC Cancer</i> , 2014, 14, 166.	1.1	23
570	Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool. <i>BMC Health Services Research</i> , 2014, 14, 537.	0.9	9
571	The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?. <i>Pathology</i> , 2014, 46, 121-125.	0.3	7
572	Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study. <i>Annals of Oncology</i> , 2014, 25, 1854-1860.	0.6	40
573	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii113-iii123.	0.6	212
574	Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 578-583.	0.6	149
575	Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. <i>BMC Cancer</i> , 2014, 14, 632.	1.1	13
576	Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. <i>European Journal of Cancer</i> , 2014, 50, 388-396.	1.3	34

#	ARTICLE	IF	CITATIONS
577	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. <i>Targeted Oncology</i> , 2014, 9, 273-277.	1.7	23
578	A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. <i>Investigational New Drugs</i> , 2014, 32, 171-177.	1.2	11
579	Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 730-734.	0.6	91
580	Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 735-742.	0.6	149
581	Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors. <i>Value in Health</i> , 2014, 17, A624.	0.1	2
582	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. <i>Clinical Sarcoma Research</i> , 2014, 4, 7.	2.3	47
583	Workshop report on the 2nd Joint ENCCA/EuroSARC European bone sarcoma network meeting: integration of clinical trials with tumour biology. <i>Clinical Sarcoma Research</i> , 2014, 4, 4.	2.3	2
584	Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. <i>BMC Cancer</i> , 2014, 14, 156.	1.1	32
585	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 1137-1147.	1.3	104
586	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014, 50, 679-689.	1.3	40
587	Primary cardiac sarcomas: A retrospective study of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 128-136.	1.3	122
588	Targeted imaging of β -catenin expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: A potential tool to reduce incomplete surgical resection. <i>Bone</i> , 2014, 62, 71-78.	1.4	13
589	Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. <i>Cancer Treatment Reviews</i> , 2014, 40, 242-247.	3.4	32
590	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy. <i>Cancer Cell</i> , 2014, 25, 846-859.	7.7	1,033
591	Conservative surgery vs. duodeno-pancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): A retrospective review of 114 patients from the French Sarcoma Group (FSG). <i>European Journal of Surgical Oncology</i> , 2014, 40, 1369-1375.	0.5	25
592	Targeted polytherapy in small cell sarcoma and its association with doxorubicin. <i>Molecular Oncology</i> , 2014, 8, 1458-1468.	2.1	12
593	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 415-423.	5.1	864
594	Oncogènes, gènes suppresseurs de tumeurs, et aneuploïdie : la somme de toutes les nuances. <i>Bulletin Du Cancer</i> , 2014, 101, 340.	0.6	0

#	ARTICLE	IF	CITATIONS
595	ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).. Journal of Clinical Oncology, 2014, 32, 10501-10501.	0.8	8
596	Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).. Journal of Clinical Oncology, 2014, 32, 10504-10504.	0.8	6
597	Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcoma (ASTS).. Journal of Clinical Oncology, 2014, 32, 10523-10523.	0.8	3
598	Correlation of <i>KIT</i> and <i>PDGFRA</i> mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. Journal of Clinical Oncology, 2014, 32, 10549-10549.	0.8	1
599	Pazopanib in uterine sarcoma (Uts): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).. Journal of Clinical Oncology, 2014, 32, 10579-10579.	0.8	2
600	Vulnerable populations and overconfidence in cancer screening.. Journal of Clinical Oncology, 2014, 32, 1574-1574.	0.8	2
601	VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. Journal of Clinical Oncology, 2014, 32, 2533-2533.	0.8	12
602	Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. Journal of Clinical Oncology, 2014, 32, 2535-2535.	0.8	36
603	Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.. Journal of Clinical Oncology, 2014, 32, 2621-2621.	0.8	1
604	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 3518-3518.	0.8	20
605	Breast cancer screening controversy: Impact on other cancer screening programs.. Journal of Clinical Oncology, 2014, 32, e12507-e12507.	0.8	1
606	Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acs@ Program.. Journal of Clinical Oncology, 2014, 32, TPS2647-TPS2647.	0.8	2
607	Utility of 18F-FDG PET with a Semi-Quantitative Index in the Detection of Sarcomatous Transformation in Patients with Neurofibromatosis Type 1. PLoS ONE, 2014, 9, e85954.	1.1	51
608	A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS).. Journal of Clinical Oncology, 2014, 32, 10525-10525.	0.8	0
609	Improved survival in an exhaustive population based on a cohort of liposarcoma (LPS) patients treated in expert centers according to clinical practice guidelines (CPG'S): Experience from Rhone Alpes (RA) region.. Journal of Clinical Oncology, 2014, 32, 10581-10581.	0.8	0
610	ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progression in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2014, 32, 3033-3033.	0.8	1
611	Abstract 2574: Interleukin-7 (CYT107) treatment in lymphopenic 1st line metastatic breast carcinoma patients treated with chemotherapy regimen (Capecitabine) favors the restoration of T-cell subsets number. , 2014, , .		0
612	Abstract 2780: Tyro3 and Axl receptors tyrosine kinase as potential therapeutic targets in leiomyosarcoma. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
613	Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients. , 2014, , .		0
614	Abstract 1109: The antimicrobial peptide LL37 activates plasmacytoid dendritic cells in breast cancer. , 2014, , .		0
615	Abstract LB-253: A comprehensive evaluation of immune checkpoints ligands (ICPLs) in more than 1,000 cancer cell lines (CCLs) identifies specific expression patterns. , 2014, , .		0
616	Abstract 2940: Comprehensive biomarker program demonstrates proof of mechanism and modulation of the tumor microenvironment due to RG7155, a novel therapeutic antibody targeting tumor associated macrophages. , 2014, , .		0
617	The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study. <i>Blood</i> , 2014, 124, 635-635.	0.6	2
618	Updated Results Confirm Favorable Outcome of Immunocompetent Patients with Primary CNS Lymphoma Treated By C5R Protocol in Combination with Intravenous Rituximab and Intrathecal Liposomal Cytarabine: A Multicentric Prospective Phase 2 Study of the Lymphoma Study Association (LYSA). <i>Blood</i> , 2014, 124, 3060-3060.	0.6	0
619	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. <i>Clinical Sarcoma Research</i> , 2013, 3, 8.	2.3	38
620	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 901-908.	5.1	487
621	Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. <i>BMC Cancer</i> , 2013, 13, 109.	1.1	62
622	Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. <i>BMC Cancer</i> , 2013, 13, 64.	1.1	66
623	Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. <i>Targeted Oncology</i> , 2013, 8, 261-269.	1.7	10
624	Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. <i>European Journal of Cancer</i> , 2013, 49, 449-456.	1.3	37
625	Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2013, 73, 3499-3510.	0.4	277
626	Breast cancerâ€ derived transforming growth factorâ€ ² and tumor necrosis factorâ€ ¹ compromise interferonâ€ ¹ production by tumorâ€ associated plasmacytoid dendritic cells. <i>International Journal of Cancer</i> , 2013, 133, 771-778.	2.3	80
627	Advanced chondrosarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2013, 24, 2916-2922.	0.6	184
628	A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours. <i>British Journal of Cancer</i> , 2013, 109, 2574-2578.	2.9	25
629	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. <i>European Journal of Cancer</i> , 2013, 49, 2531-2541.	1.3	41
630	Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment. <i>Cancer Research</i> , 2013, 73, 4629-4640.	0.4	164

#	ARTICLE	IF	CITATIONS
631	Sorafenib in patients with progressive epithelioid hemangioendothelioma. <i>Cancer</i> , 2013, 119, 2639-2644.	2.0	97
632	An Unusual Giant Cell Tumor of the Thyroid: Case Report and Review of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1-6.	1.8	53
633	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. <i>European Journal of Cancer</i> , 2013, 49, 1673-1682.	1.3	42
634	Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT. <i>Molecular Oncology</i> , 2013, 7, 323-333.	2.1	9
635	Radiation Therapy in Localized Ewing's Sarcomas: Pattern of Relapses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 801.	0.4	0
636	CD4 lymphopenia to identify end-of-life metastatic cancer patients. <i>European Journal of Cancer</i> , 2013, 49, 1080-1089.	1.3	31
637	A first-in-man phase I trial of a new monoclonal antibody labelled with yttrium 90 for radioimmunotherapy of relapsed or refractory non resectable synovial-sarcomas. <i>Physica Medica</i> , 2013, 29, e26-e27.	0.4	0
638	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013, 381, 295-302.	6.3	1,144
639	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>European Journal of Cancer</i> , 2013, 49, 1027-1031.	1.3	69
640	Trabectedin's contribution to the treatment of sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 3-9.	1.1	1
641	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013, 14, 931-939.	0.6	43
642	An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. <i>European Journal of Cancer</i> , 2013, 49, 3219-3228.	1.3	75
643	New fronts in the adjuvant treatment of GIST. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 715-723.	1.1	8
644	High frequency of <i>MYC</i> gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 93-98.	1.5	30
645	Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. <i>Hematological Oncology</i> , 2013, 31, 57-64.	0.8	19
646	A decade of change in the treatment of advanced soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1-2.	1.1	9
647	Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. <i>Annals of Oncology</i> , 2013, 24, 1087-1093.	0.6	80
648	Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. <i>Annals of Oncology</i> , 2013, 24, 784-791.	0.6	42

#	ARTICLE	IF	CITATIONS
649	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. <i>Annals of Oncology</i> , 2013, 24, 537-542.	0.6	39
650	Primary leptomeningeal lymphoma. <i>Neurology</i> , 2013, 81, 1690-1696.	1.5	70
651	Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2485-2492.	0.8	213
652	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. <i>Annals of Oncology</i> , 2013, 24, 2681-2685.	0.6	19
653	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. <i>Annals of Oncology</i> , 2013, 24, 1924-1930.	0.6	43
654	Impact of Molecular Analysis on the Final Sarcoma Diagnosis. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1259-1268.	2.1	55
655	GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. <i>Annals of Oncology</i> , 2013, 24, 2922-2926.	0.6	74
656	Genetic Profiling Identifies Two Classes of Soft-Tissue Leiomyosarcomas with Distinct Clinical Characteristics. <i>Clinical Cancer Research</i> , 2013, 19, 1190-1196.	3.2	46
657	Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis: an EORTC STBSG and ROG study (EORTC 62991/22998). <i>Annals of Oncology</i> , 2013, 24, 2672-2676.	0.6	115
658	ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 ⁺ T cells by plasmacytoid dendritic cells. <i>Oncolimmunology</i> , 2013, 2, e23185.	2.1	61
659	Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. <i>British Journal of Cancer</i> , 2013, 109, 1717-1724.	2.9	55
660	A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. <i>British Journal of Cancer</i> , 2013, 109, 909-914.	2.9	54
661	Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression. <i>Oncologist</i> , 2013, 18, 1192-1199.	1.9	15
662	Plasmacytoid dendritic cells deficient in IFN γ production promote the amplification of FOXP3 ⁺ regulatory T cells and are associated with poor prognosis in breast cancer patients. <i>Oncolimmunology</i> , 2013, 2, e22338.	2.1	46
663	Molecular characterisation of gastrointestinal stromal tumours in a South African population. <i>Oncology Letters</i> , 2013, 5, 155-160.	0.8	8
664	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST. , 2013, , .		4
665	Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse. <i>Blood</i> , 2013, 122, 933-933.	0.6	1
666	Do Our Current Clinical Trial Designs Help to Guide Clinical Practice?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e381-e385.	1.8	1

#	ARTICLE	IF	CITATIONS
667	Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.. Journal of Clinical Oncology, 2013, 31, 10500-10500.	0.8	32
668	Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2013, 31, 10501-10501.	0.8	8
669	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. Journal of Clinical Oncology, 2013, 31, 10503-10503.	0.8	26
670	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. Journal of Clinical Oncology, 2013, 31, 10514-10514.	0.8	17
671	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. Journal of Clinical Oncology, 2013, 31, 10516-10516.	0.8	8
672	Impact of mutational status and other prognostic factors on survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.. Journal of Clinical Oncology, 2013, 31, 10548-10548.	0.8	2
673	A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma.. Journal of Clinical Oncology, 2013, 31, 10563-10563.	0.8	3
674	Gene Expression Patterns of Hemizygous and Heterozygous KIT Mutations Suggest Distinct Oncogenic Pathways: A Study in NIH3T3 Cell Lines and GIST Samples. PLoS ONE, 2013, 8, e61103.	1.1	9
675	Abstract A22: Overcoming therapeutic MAb resistance in aggressive HER2-positive breast carcinomas by adoptive immunotherapy using optimized effectors cells. , 2013, , .		0
676	Knowledge of the French population on colorectal cancer screening: Data from the EDIFICE 3 survey.. Journal of Clinical Oncology, 2013, 31, 352-352.	0.8	0
677	Do Our Current Clinical Trial Designs Help to Guide Clinical Practice?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e381-e385.	1.8	0
678	Abstract C260: Dual targeting of the PI3K/Akt/mTOR pathway significantly delays chondrosarcoma progression and relapse.. , 2013, , .		0
679	Abstract P2-04-05: Pros and cons of breast cancer screening: Knowledge in lay women. , 2013, , .		0
680	Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas. Journal of Clinical Oncology, 2012, 30, 78-84.	0.8	238
681	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. Sarcoma, 2012, 2012, 1-11.	0.7	50
682	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Annals of Oncology, 2012, 23, 1659-1665.	0.6	18
683	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Annals of Oncology, 2012, 23, 2763-2770.	0.6	61
684	Desmoplastic Small Round Cell Tumor: Current Management and Recent Findings. Sarcoma, 2012, 2012, 1-5.	0.7	89

#	ARTICLE	IF	CITATIONS
685	Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. <i>Annals of Oncology</i> , 2012, 23, 517-523.	0.6	91
686	Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2012, 17, 260-266.	1.9	170
687	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. <i>Clinical Cancer Research</i> , 2012, 18, 3170-3179.	3.2	116
688	Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii92-vii99.	0.6	136
689	Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. <i>Annals of Oncology</i> , 2012, 23, 1680-1687.	0.6	120
690	Reply to Y. Nishida et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1391-1391.	0.8	0
691	Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). <i>Oncologist</i> , 2012, 17, 1213-1220.	1.9	182
692	Depression assessment by oncologists and palliative care physicians. <i>Palliative and Supportive Care</i> , 2012, 10, 255-263.	0.6	10
693	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. <i>Oncolmmunology</i> , 2012, 1, 380-382.	2.1	114
694	Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. <i>Oncolmmunology</i> , 2012, 1, 759-761.	2.1	25
695	Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. <i>British Journal of Cancer</i> , 2012, 107, 639-645.	2.9	47
696	Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. <i>Annals of Oncology</i> , 2012, 23, 771-776.	0.6	129
697	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii49-vii55.	0.6	174
698	Technology & tools development. <i>Annals of Oncology</i> , 2012, 23, v33-v37.	0.6	0
699	ICOS-Ligand Expression on Plasmacytoid Dendritic Cells Supports Breast Cancer Progression by Promoting the Accumulation of Immunosuppressive CD4+ T Cells. <i>Cancer Research</i> , 2012, 72, 6130-6141.	0.4	184
700	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone. <i>Clinical Cancer Research</i> , 2012, 18, 4415-4424.	3.2	372
701	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2012, 23, 1601-1607.	0.6	117
702	Adjuvant therapy in primary GIST: state-of-the-art. <i>Annals of Oncology</i> , 2012, 23, 2776-2781.	0.6	67

#	ARTICLE	IF	CITATIONS
703	Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. <i>Clinical Cancer Research</i> , 2012, 18, 4458-4464.	3.2	194
704	Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. <i>Annals of Oncology</i> , 2012, 23, 2442-2449.	0.6	179
705	Adhesion to Clinical Practices Guidelines (CPG'S) and Role on Survival for Soft Tissue Sarcoma Patients. Analysis of a Population Based Cohort from Rhone-Alpes Region. <i>Annals of Oncology</i> , 2012, 23, ix478.	0.6	12
706	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncolmmunology</i> , 2012, 1, 432-440.	2.1	102
707	From Empirical to Rational Treatment of Human Cancers Cells and their Stroma. <i>Annals of Oncology</i> , 2012, 23, ix21.	0.6	0
708	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2012, 379, 1879-1886.	6.3	1,752
709	Impaired IFN- γ Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. <i>Cancer Research</i> , 2012, 72, 5188-5197.	0.4	285
710	Personalised medicine in oncology: questions for the next 20 years. <i>Lancet Oncology, The</i> , 2012, 13, 448-449.	5.1	19
711	Pazopanib for metastatic soft-tissue sarcoma – Authors' reply. <i>Lancet, The</i> , 2012, 380, 801.	6.3	4
712	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2012, 48, 3036-3044.	1.3	129
713	334 Gene Expression Analysis of Human Sarcoma Tissues to Explore Clinical Outcomes of mTOR Inhibition with Ridaforolimus: Correlative Science From the Phase III SUCCEED Trial Testing Maintenance Therapy for Metastatic Disease. <i>European Journal of Cancer</i> , 2012, 48, 102.	1.3	0
714	43 Targeting the PI3K/mTOR Pathway for Sarcoma Treatment: Investigation in Rat Syngeneic Chondrosarcoma Model. <i>European Journal of Cancer</i> , 2012, 48, 15.	1.3	2
715	Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). <i>Annals of Oncology</i> , 2012, 23, 182-186.	0.6	130
716	Giant-cell tumor of bone, anti-RANKL therapy. <i>BoneKEy Reports</i> , 2012, 1, 149.	2.7	30
717	First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study. <i>European Journal of Cancer</i> , 2012, 48, 547-563.	1.3	64
718	Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: A predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. <i>European Journal of Cancer</i> , 2012, 48, 3027-3035.	1.3	104
719	Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. <i>BMC Health Services Research</i> , 2012, 12, 82.	0.9	57
720	Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. <i>Clinical Sarcoma Research</i> , 2012, 2, 11.	2.3	2

#	ARTICLE	IF	CITATIONS
721	Management of imatinib-associated skin rash in a patient with metastatic gastrointestinal stromal tumor: a case report. <i>Clinical Sarcoma Research</i> , 2012, 2, 23.	2.3	1
722	Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. <i>Cancer Genetics</i> , 2012, 205, 657-664.	0.2	6
723	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology</i> , The, 2012, 13, 1133-1140.	5.1	490
724	CA1 Discordant Diagnoses in Sarcoma, GIST and Desmoide Tumour in France: Results From the Network RREPS. <i>Value in Health</i> , 2012, 15, A285.	0.1	0
725	Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. <i>Medical Oncology</i> , 2012, 29, 1765-1772.	1.2	95
726	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. <i>Medical Oncology</i> , 2012, 29, 3003-3008.	1.2	13
727	PRM143 Cluster Analysis and Principal Component Analysis to Assess the Variability of Data in Cost Evaluations: Methods and Applications in Oncology. <i>Value in Health</i> , 2012, 15, A486.	0.1	0
728	Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committeesâ€™ organization. <i>Bulletin Du Cancer</i> , 2012, 99, E34-E42.	0.6	16
729	Randomized Phase 3 Trial of Regorafenib in Patients (Patients) with Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Progressing Despite Prior Treatment with at Least Imatinib (IM) and Sunitinib (SU) : Grid Trial. <i>Annals of Oncology</i> , 2012, 23, xi20.	0.6	7
730	Efficacy and Safety of Denosumab in Giant Cell Tumor of Bone: Updated Results with Independent Radiographic Assessment of Response. <i>Annals of Oncology</i> , 2012, 23, ix479.	0.6	0
731	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012, 23, ix478-ix479.	0.6	3
732	P3.13 Immune Status Stratification of Metastatic Breast Cancer Patients: Lympho-Divpenia Predicts Overall Survival. <i>Annals of Oncology</i> , 2012, 23, v37.	0.6	0
733	Pazopanib for the treatment of soft-tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2012, 4, 65.	0.8	14
734	Desmoplastic small round cell tumors with EWSâ€™WT1 fusion transcript in children and young adults. <i>Pediatric Blood and Cancer</i> , 2012, 58, 891-897.	0.8	45
735	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012, 118, 3330-3336.	2.0	118
736	Incidence of soft tissue sarcoma and beyond. <i>Cancer</i> , 2012, 118, 5339-5348.	2.0	210
737	High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. <i>Annals of Oncology</i> , 2012, 23, 777-784.	0.6	21
738	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012, 30, 1193-1202.	1.2	71

#	ARTICLE	IF	CITATIONS
739	Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. <i>Annals of Surgical Oncology</i> , 2012, 19, 1551-1559.	0.7	57
740	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012, 118, 1649-1655.	2.0	222
741	Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. <i>Investigational New Drugs</i> , 2012, 30, 765-771.	1.2	57
742	Abstract 4447: In search of the ideal cancer screening test. , 2012, , .		6
743	First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis. <i>Blood</i> , 2012, 120, 3655-3655.	0.6	1
744	A Multicentric Prospective Phase 2 Study of Intravenous Rituximab and Intrathecal Liposomal Cytarabine in Combination with C5R Protocol Followed by Brain Radiotherapy for Immunocompetent Patients with Primary CNS Lymphoma: A Lymphoma Study Association (LYSA) Trial. <i>Blood</i> , 2012, 120, 796-796.	0.6	3
745	Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10007-10007.	0.8	3
746	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10009-10009.	0.8	4
747	Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 10020-10020.	0.8	4
748	Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10056-10056.	0.8	1
749	Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10089-10089.	0.8	2
750	Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10092-10092.	0.8	3
751	Phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13600-e13600.	0.8	20
752	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	0.8	2
753	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA10008-LBA10008.	0.8	11
754	Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model. <i>PLoS ONE</i> , 2012, 7, e32458.	1.1	54
755	Screening for colorectal cancer in France: Third edition of the EDIFICE survey.. <i>Journal of Clinical Oncology</i> , 2012, 30, 411-411.	0.8	0
756	Abstract 5578: IGF-1R nuclear staining in tumor cells identifies sarcoma patients with a prolonged progression free survival after IGF-1R monoclonal antibody therapy. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
757	Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. <i>Discovery Medicine</i> , 2012, 13, 357-67.	0.5	27
758	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 5423-5434.	0.4	200
759	Therapeutic pipeline for soft-tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2479-2491.	0.9	9
760	8038 POSTER Lymphopenia is an Independent Prognostic Factor in Ovarian Cancer and Could Be Associated With Immune Activation. <i>European Journal of Cancer</i> , 2011, 47, S538-S539.	1.3	0
761	Management of gastrointestinal stromal tumours of limited size: Proposals from a French panel of physicians. <i>Digestive and Liver Disease</i> , 2011, 43, 935-939.	0.4	4
762	9401 ORAL Chemotherapy Treatment Patterns in Patients With Metastatic Soft Tissue Sarcoma – the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. <i>European Journal of Cancer</i> , 2011, 47, S663.	1.3	0
763	9400 ORAL Prognostic and Predictive Factors in Advanced Soft Tissue Sarcoma Patients Treated in an EORTC STBSG Global Network Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo (EORTC 62072, PALETTE). <i>European Journal of Cancer</i> , 2011, 47, S662.	1.3	0
764	PCN76 Cost-Effectiveness Analysis of Compliance with Clinical Practice Guidelines in Sarcoma Treatment: An Economic Evaluation in Two European Regions. <i>Value in Health</i> , 2011, 14, A448.	0.1	0
765	A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. <i>Cancer Treatment Reviews</i> , 2011, 37, 373-384.	3.4	49
766	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. <i>European Journal of Cancer</i> , 2011, 47, 1006-1012.	1.3	88
767	Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?. <i>European Journal of Cancer</i> , 2011, 47, S385-S388.	1.3	3
768	338 INVITED Soft Tissue Sarcoma as a Model for Targeted Treatment and Drug Development. <i>European Journal of Cancer</i> , 2011, 47, S76.	1.3	0
769	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. <i>Lancet Oncology</i> , The, 2011, 12, 1045-1052.	5.1	212
770	miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. <i>Sarcoma</i> , 2011, 2011, 1-13.	0.7	15
771	Breast cancer screening in women aged 50–74 years. <i>European Journal of Cancer Prevention</i> , 2011, 20, S8-S12.	0.6	9
772	Use of F-18 FDG PET/CT in Non-Hodgkin Lymphoma With Central Nervous System Involvement. <i>Clinical Nuclear Medicine</i> , 2011, 36, e45-e49.	0.7	5
773	Uptake of breast cancer screening in women aged over 75years. <i>European Journal of Cancer Prevention</i> , 2011, 20, S13-S15.	0.6	3
774	Screening for prostate cancer. <i>European Journal of Cancer Prevention</i> , 2011, 20, S33-S35.	0.6	4

#	ARTICLE	IF	CITATIONS
775	Impact of awareness of cancer among acquaintances on cancer screening attendance. <i>European Journal of Cancer Prevention</i> , 2011, 20, S36-S38.	0.6	5
776	Mammography utilization in women aged 40-49 years. <i>European Journal of Cancer Prevention</i> , 2011, 20, S16-S19.	0.6	8
777	Organized colorectal cancer screening programmes. <i>European Journal of Cancer Prevention</i> , 2011, 20, S20-S25.	0.6	9
778	Impact of general practitioners' sex and age on systematic recommendation for cancer screening. <i>European Journal of Cancer Prevention</i> , 2011, 20, S39-S41.	0.6	16
779	CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. <i>Blood</i> , 2011, 118, 5130-5140.	0.6	42
780	Increasing Coverage Rates for Mammographic Screening in France in Older Women-16 Years of Follow-Up. <i>Breast Journal</i> , 2011, 17, 686-688.	0.4	1
781	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011, 17, 700-707.	15.2	282
782	Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma. <i>British Journal of Cancer</i> , 2011, 104, 1544-1550.	2.9	33
783	Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor. <i>Seminars in Oncology</i> , 2011, 38, S3-S9.	0.8	104
784	The Evolution of a Revolutionary Class: Extending Benefits of Tyrosine Kinase Inhibitors-Introduction. <i>Seminars in Oncology</i> , 2011, 38, S1-S2.	0.8	0
785	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 187-195. ^{1,1}		10
786	Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 69-77.	1.1	49
787	Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. <i>BMC Cancer</i> , 2011, 11, 213.	1.1	31
788	Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. <i>BMC Cancer</i> , 2011, 11, 72.	1.1	101
789	Validation of prognostic scores for survival in cancer patients beyond first-line therapy. <i>BMC Cancer</i> , 2011, 11, 95.	1.1	33
790	Trends in survival for patients with metastatic soft-tissue sarcoma. <i>Cancer</i> , 2011, 117, 1049-1054.	2.0	237
791	<i>ERCC5</i> , <i>XPG</i> , <i>ERCC1</i> and <i>BRCA1</i> gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011, 117, 3445-3456.	2.0	57
792	Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. <i>Hematological Oncology</i> , 2011, 29, 10-16.	0.8	23

#	ARTICLE	IF	CITATIONS
793	MicroRNA profiles in osteosarcoma as a predictive tool for ifosfamide response. International Journal of Cancer, 2011, 129, 680-690.	2.3	129
794	Combination therapy for gastrointestinal stromal tumors: evidence from recent clinical trials. Clinical Investigation, 2011, 1, 825-836.	0.0	1
795	Gastrointestinal stromal tumors of the stomach and duodenum. Current Opinion in Gastroenterology, 2011, 27, 571-575.	1.0	10
796	Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Annals of Oncology, 2011, 22, 452-457.	0.6	193
797	Tumeurs stromales gastro-intestinales. , 2011, , 305-325.		1
798	Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Annals of Oncology, 2011, 22, 1266-1272.	0.6	69
799	Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clinical Cancer Research, 2011, 17, 346-352.	3.2	55
800	Updating progress in sarcoma therapy with mTOR inhibitors. Annals of Oncology, 2011, 22, 280-287.	0.6	45
801	Added value of molecular targeted agents in oncology. Annals of Oncology, 2011, 22, 1703-1716.	0.6	49
802	Prognostic Factors Influencing Progression-Free Survival Determined From a Series of Sporadic Desmoid Tumors: A Wait-and-See Policy According to Tumor Presentation. Journal of Clinical Oncology, 2011, 29, 3553-3558.	0.8	313
803	Early Detection of Tumor Cells by Innate Immune Cells Leads to Treg Recruitment through CCL22 Production by Tumor Cells. Cancer Research, 2011, 71, 6143-6152.	0.4	100
804	Usefulness of Positron Emission Tomography Using 18F-FDG Performed At Diagnosis and During Initial Chemotherapy for Imaging Primary Central Nervous System Lymphoma: A 24 Immunocompetent patient's Study.. Blood, 2011, 118, 1597-1597.	0.6	4
805	Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing. PLoS ONE, 2011, 6, e20294.	1.1	428
806	Abstract LB-165: Low TCR diversity (divpenia) is a new prognosis factor of overall survival in metastatic breast cancer. , 2011, , .		0
807	Abstract 2267: Long term prognostic impact of CD4 and CD8 lymphopenia and rapid recovery in a cohort of 220 patients with a 10 years follow-up. , 2011, , .		0
808	Abstract 1784: Comparing genetically engineered T cells for chimeric TCR versus CD16 + Herceptin for adoptive immunotherapy against HER2 positive breast carcinomas. , 2011, , .		0
809	Evaluation in the Context of Daily Practice of Follicular Lymphoma patients' Outcome Before and After Approval of Rituximab in First Line Therapy in This Indication: Results of a Retrospective Analysis of 247 Unselected Patients with a 5-Year Median of Follow-up,. Blood, 2011, 118, 3698-3698.	0.6	1
810	Prognostic Value of 18F-FDG Positron Emission Tomography Used for Assessment of the First Line Therapy in 410 Diffuse Large B-Cell Lymphoma Patients: A Daily Practice Evaluation Before and After the Prescription of This Metabolic Imaging Technique,. Blood, 2011, 118, 3686-3686.	0.6	0

#	ARTICLE	IF	CITATIONS
811	Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. <i>Anti-Cancer Drugs</i> , 2010, 21, 113-119.	0.7	27
812	Serum cytokines in follicular lymphoma. Correlation of TGF- β 2 and VEGF with survival. <i>Annals of Hematology</i> , 2010, 89, 25-33.	0.8	34
813	2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 31-46.	2.0	78
814	Molecular response prediction in gastrointestinal stromal tumors. <i>Targeted Oncology</i> , 2010, 5, 29-37.	1.7	7
815	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , 2010, 28, 76-82.	1.2	26
816	Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. <i>BMC Cancer</i> , 2010, 10, 150.	1.1	78
817	The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2010, 116, 1847-1858.	2.0	30
818	Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. <i>Cancer</i> , 2010, 116, 5126-5137.	2.0	60
819	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. <i>Histopathology</i> , 2010, 57, 259-270.	1.6	162
820	High frequency of β -catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. <i>British Journal of Cancer</i> , 2010, 102, 1032-1036.	2.9	130
821	A prospective epidemiological study of new incident GISTs during two consecutive years in RhÃ´ne Alpes region: incidence and molecular distribution of GIST in a European region. <i>British Journal of Cancer</i> , 2010, 103, 165-170.	2.9	108
822	Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. <i>British Journal of Cancer</i> , 2010, 103, 482-485.	2.9	35
823	Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. <i>Nature Medicine</i> , 2010, 16, 781-787.	15.2	394
824	Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. <i>Bulletin Du Cancer</i> , 2010, 97, E33-E36.	0.6	9
825	R60 "Oral: Valeur predictive d'une signature d'expression basÃ©e sur la complexitÃ© gÃ©nomique.. <i>Bulletin Du Cancer</i> , 2010, 97, S38-S39.	0.6	0
826	Tumeurs stromales gastro-intestinales (GIST)., 2010, , 149-154.		0
827	Imatinib mesylate for the treatment of gastrointestinal stromal tumor. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 623-634.	1.1	16
828	Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v98-v102.	0.6	220

#	ARTICLE	IF	CITATIONS
829	Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. <i>Annals of Oncology</i> , 2010, 21, 208-215.	0.6	47
830	Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Étude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , 2010, 21, 842-850.	0.6	56
831	Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. <i>Annals of Oncology</i> , 2010, 21, 2436-2441.	0.6	112
832	A phase II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. <i>Annals of Oncology</i> , 2010, 21, 1990-1998.	0.6	114
833	The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists. <i>Bulletin Du Cancer</i> , 2010, 97, E16-E22.	0.6	47
834	Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v198-v203.	0.6	232
835	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas. <i>European Journal of Cancer</i> , 2010, 46, 72-83.	1.3	224
836	Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). <i>European Journal of Cancer</i> , 2010, 46, 1344-1351.	1.3	118
837	Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). <i>European Journal of Cancer</i> , 2010, 46, 2206-2215.	1.3	94
838	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2010, 11, 275-280.	5.1	607
839	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. <i>Lancet Oncology</i> , The, 2010, 11, 561-570.	5.1	576
840	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 942-949.	5.1	260
841	Towards global consensus in the treatment of gastrointestinal stromal tumor. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 221-232.	1.1	28
842	Abstract 1780: p53 mutation predicts limited benefit from adjuvant chemotherapy in patients with localized completely resected high grade soft tissue sarcoma: a retrospective study on 117 patients of the French Sarcoma Group. , 2010, , .		1
843	Vue générale. , 2010, , 145-147.		0
844	Abstract 2699: ERCC5 (XPG) status and clinical activity of trabectedin in patients with advanced soft-tissue sarcoma. , 2010, , .		0
845	Prognostic Impact of Elevated Serum Ferritin at Diagnosis of Diffuse Large B-Cell Lymphoma Treated In the Rituximab Era. <i>Blood</i> , 2010, 116, 5080-5080.	0.6	0
846	Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. <i>Bulletin Du Cancer</i> , 2009, 96, E30-E44.	0.6	24

#	ARTICLE	IF	CITATIONS
847	Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti-IL-6 Antibody. <i>PLoS ONE</i> , 2009, 4, e8026.	1.1	19
848	Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 831-838.	1.1	28
849	Trabectedin for the management of soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 727-737.	1.1	6
850	Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv132-iv136.	0.6	76
851	Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. <i>Annals of Oncology</i> , 2009, 20, 425-430.	0.6	129
852	Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). <i>Journal of Clinical Oncology</i> , 2009, 27, 3126-3132.	0.8	611
853	Absence of Progression As Assessed by Response Evaluation Criteria in Solid Tumors Predicts Survival in Advanced GI Stromal Tumors Treated With Imatinib Mesylate: The Intergroup EORTC-ISC-AGITG Phase III Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 3969-3974.	0.8	95
854	Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv64-iv67.	0.6	158
855	Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?. <i>Oncology</i> , 2009, 77, 157-161.	0.9	2
856	Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules. <i>Journal of Clinical Oncology</i> , 2009, 27, 4188-4196.	0.8	472
857	A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin \pm : a prospective randomized controlled trial of the ELYPSE study group. <i>Annals of Oncology</i> , 2009, 20, 1105-1112.	0.6	20
858	New paradigms in gastrointestinal stromal tumour management. <i>Annals of Oncology</i> , 2009, 20, i18-i24.	0.6	18
859	Natural Killer Cell IFN- γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients. <i>Cancer Research</i> , 2009, 69, 3563-3569.	0.4	181
860	2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. <i>Annals of Oncology</i> , 2009, 20, 1459-1471.	0.6	116
861	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. <i>Cancer Research</i> , 2009, 69, 5383-5391.	0.4	610
862	Adjuvant Chemotherapy in Localized Soft Tissue Sarcomas: Still Not Proven. <i>Oncologist</i> , 2009, 14, 1013-1020.	1.9	51
863	Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4191-4198.	3.2	61
864	A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 5910-5916.	3.2	101

#	ARTICLE	IF	CITATIONS
865	Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series. <i>Clinical Breast Cancer</i> , 2009, 9, 118-121.	1.1	58
866	Sarcomas With Spindle Cell Morphology. <i>Seminars in Oncology</i> , 2009, 36, 324-337.	0.8	28
867	Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. <i>Investigational New Drugs</i> , 2009, 27, 482-489.	1.2	37
868	Prognosis and predictive value of KIT exon 11 deletion in GISTs. <i>British Journal of Cancer</i> , 2009, 101, 7-11.	2.9	41
869	Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. <i>Cancer Research</i> , 2009, 69, 2000-2009.	0.4	617
870	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). <i>European Journal of Cancer</i> , 2009, 45, 1103-1106.	1.3	31
871	Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. <i>European Journal of Cancer</i> , 2009, 45, 1959-1968.	1.3	333
872	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. <i>European Journal of Cancer</i> , 2009, 45, 2333-2341.	1.3	75
873	1260 Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). <i>European Journal of Cancer. Supplement</i> , 2009, 7, 138-139.	2.2	0
874	3504 General Practitioner's attitudes towards cancer screening "Does gender still matter?". <i>European Journal of Cancer. Supplement</i> , 2009, 7, 203.	2.2	0
875	1LBA Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STs): Results of the randomized EORTC-ESHO intergroup trial (NCI-00003052). <i>European Journal of Cancer. Supplement</i> , 2009, 7, 2.	2.2	5
876	Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated With Local Control. <i>Journal of Clinical Oncology</i> , 2009, 27, 31-37.	0.8	528
877	PCN10 MALIGNANT GASTROINTESTINAL STROMAL TUMORS TREATED WITH IMATINIB IN FRANCE: EFFICACY IN REAL LIFE. <i>Value in Health</i> , 2009, 12, A257-A258.	0.1	0
878	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. <i>European Journal of Cancer. Supplement</i> , 2009, 7, 590.	2.2	2
879	9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. <i>European Journal of Cancer. Supplement</i> , 2009, 7, 590-591.	2.2	3
880	9415 Malignant gastrointestinal stromal tumours treated with imatinib in France: results in unselected patients. <i>European Journal of Cancer. Supplement</i> , 2009, 7, 594.	2.2	0
881	9427 Efficacy of second-line trabectedin in patients with advanced liposarcomas and leiomyosarcomas progressing despite prior conventional chemotherapy. <i>European Journal of Cancer. Supplement</i> , 2009, 7, 598.	2.2	3
882	Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?. <i>Current Opinion in Oncology</i> , 2009, 21, 360-366.	1.1	11

#	ARTICLE	IF	CITATIONS
883	Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs. American Journal of Surgical Pathology, 2009, 33, 157-158.	2.1	12
884	Mapping the literature: Role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. Drugs of Today, 2009, 45, 403.	0.7	13
885	Gastrointestinal stromal tumours. , 2009, , 137-148.		0
886	Use of Chemotherapy and Immunotherapy the Last Four Weeks of life in Patients with Lymphoma in An Anticancer Center with Focus On the Impact of Time Period (1998-2002 and 2003-2008).. Blood, 2009, 114, 4537-4537.	0.6	0
887	Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.. Blood, 2009, 114, 2702-2702.	0.6	0
888	Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte.. Blood, 2009, 114, 101-101.	0.6	0
889	Accomplishments in 2008 in the management of gastrointestinal stromal tumors. Gastrointestinal Cancer Research: GCR, 2009, 3, S67-72.	0.8	0
890	Cancer screening in France: subjects' and physicians' attitudes. Cancer Causes and Control, 2008, 19, 431-434.	0.8	23
891	Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Current Gastroenterology Reports, 2008, 10, 555-561.	1.1	10
892	A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer, 2008, 113, 2532-2538.	2.0	22
893	Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication. Hematological Oncology, 2008, 26, 139-147.	0.8	6
894	Impact of organised programs on colorectal cancer screening. BMC Cancer, 2008, 8, 104.	1.1	20
895	Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. European Journal of Surgical Oncology, 2008, 34, 462-468.	0.5	263
896	Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. European Journal of Cancer, 2008, 44, 1855-1860.	1.3	34
897	Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group. European Journal of Cancer, 2008, 44, 2433-2436.	1.3	208
898	Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii35-ii38.	0.6	138
899	Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study. Journal of Clinical Oncology, 2008, 26, 5269-5274.	0.8	569
900	<i>KIT</i> Mutations Induce Intracellular Retention and Activation of an Immature Form of the KIT Protein in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2008, 14, 2285-2294.	3.2	71

#	ARTICLE	IF	CITATIONS
901	Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008, 19, ii89-ii93.	0.6	101
902	Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. <i>Clinical Cancer Research</i> , 2008, 14, 8308-8313.	3.2	20
903	Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). <i>Annals of Oncology</i> , 2008, 19, 821-822.	0.6	137
904	A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens. <i>Oncologist</i> , 2008, 13, 467-473.	1.9	53
905	Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas. <i>Oncologist</i> , 2008, 13, 1193-1200.	1.9	22
906	Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2008, 14, 6656-6662.	3.2	73
907	Primary CNS lymphoma with intraocular involvement. <i>Neurology</i> , 2008, 71, 1355-1360.	1.5	191
908	Imatinib as a Possible Cause of Severe Rhabdomyolysis. <i>New England Journal of Medicine</i> , 2008, 358, 2746-2747.	13.9	43
909	Imatinib mesilate for the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1211-1222.	0.9	19
910	Trabectedin and its potential in the treatment of soft tissue sarcoma. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 109-116.	0.9	24
911	Breast cancer screening in France: results of the EDIFICE survey. <i>International Journal of Medical Sciences</i> , 2008, 5, 106-112.	1.1	8
912	Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study. <i>Journal of Clinical Oncology</i> , 2008, 26, 10500-10500.	0.8	9
913	Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies. <i>Journal of Clinical Oncology</i> , 2008, 26, 10509-10509.	0.8	3
914	A FNCLCC French Sarcoma Group's GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). <i>Journal of Clinical Oncology</i> , 2008, 26, 10511-10511.	0.8	9
915	Detection of β -catenin mutations in primary extra-abdominal fibromatosis (EAF): An ancillary diagnostic tool. <i>Journal of Clinical Oncology</i> , 2008, 26, 10518-10518.	0.8	4
916	A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). <i>Journal of Clinical Oncology</i> , 2008, 26, 10519-10519.	0.8	12
917	Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial?. <i>Journal of Clinical Oncology</i> , 2008, 26, 10522-10522.	0.8	9
918	The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 10525-10525.	0.8	39

#	ARTICLE	IF	CITATIONS
919	Influence of complete resection of residual disease in responding patients to imatinib (IM) on the outcome of pts with advanced GIST: The experience of the BFR14 trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 10549-10549.	0.8	3
920	A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update. <i>Journal of Clinical Oncology</i> , 2008, 26, 10553-10553.	0.8	16
921	Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. <i>Journal of Clinical Oncology</i> , 2008, 26, 10554-10554.	0.8	12
922	High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low-dose TNF- α for locally advanced pelvic sarcomas and carcinomas: A phase II unicenter trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 10586-10586.	0.8	3
923	Does interruption of imatinib (IM) in responding GIST patients after one year of treatment influence the secondary resistance to IM after its reintroduction? Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 10556-10556.	0.8	1
924	Development and validation of a prediction model for early death among cancer patients participating in phase I clinical trials of new cytotoxic agents. <i>Journal of Clinical Oncology</i> , 2008, 26, 2537-2537.	0.8	0
925	Adjuvant (A) and neoadjuvant (NeoA) chemotherapy (C) in resected synovial sarcoma (SS): A study of the French Sarcoma Group (GSF-GETO). <i>Journal of Clinical Oncology</i> , 2008, 26, 10527-10527.	0.8	0
926	Outcomes for patients with advanced GIST achieving a complete remission (CR) with imatinib (IM): Results from the prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 10550-10550.	0.8	0
927	Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. <i>Blood</i> , 2008, 112, 1309-1309.	0.6	0
928	Emerging drugs for the treatment of soft tissue sarcomas. <i>Expert Opinion on Emerging Drugs</i> , 2007, 12, 139-153.	1.0	6
929	Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. <i>Annals of Oncology</i> , 2007, 18, 1851-1855.	0.6	225
930	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3144-3150.	0.8	238
931	Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007, 18, ii27-ii29.	0.6	15
932	Plasma Cytokine and Soluble Receptor Signature Predicts Outcome of Patients With Classical Hodgkin's Lymphoma: A Study From the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007, 25, 1732-1740.	0.8	108
933	Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 1107-1113.	0.8	359
934	Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. <i>Annals of Oncology</i> , 2007, 18, 2030-2036.	0.6	307
935	Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2007, 43, 308-315.	1.3	45
936	Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II " Study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2007, 43, 1017-1022.	1.3	29

#	ARTICLE	IF	CITATIONS
937	Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTC-ISC-AGITC study 62005. <i>European Journal of Cancer</i> , 2007, 43, 974-978.	1.3	101
938	Pressure-suit combined with pelvic stop-flow: A feasibility study in a bovine model. <i>European Journal of Surgical Oncology</i> , 2007, 33, 114-118.	0.5	5
939	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology</i> , The, 2007, 8, 595-602.	5.1	416
940	Chemotherapy for Osteosarcoma without High-Dose Methotrexate: Another Piece in the Puzzle. <i>Oncology Research and Treatment</i> , 2007, 30, 226-227.	0.8	11
941	Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. <i>British Journal of Haematology</i> , 2007, 138, 316-323.	1.2	70
942	Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 141-145.	0.9	39
943	Thérapeutiques moléculaires ciblées des sarcomes des tissus mous: actualités et perspectives. <i>Oncologie</i> , 2007, 9, 131-136.	0.2	0
944	Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 106-114.	2.0	3
945	Long-Term Follow-Up of 132 Immunocompetent Primary Central Nervous System Lymphomas Treated at Leon Berard Cancer Centre: Proposition of a New Prognostic Model.. <i>Blood</i> , 2007, 110, 521-521.	0.6	1
946	Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 10002-10002.	0.8	8
947	Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 10005-10005.	0.8	21
948	Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. <i>Journal of Clinical Oncology</i> , 2007, 25, 10015-10015.	0.8	10
949	Paclitaxel in patients (pts) with advanced angiosarcomas. <i>Journal of Clinical Oncology</i> , 2007, 25, 10033-10033.	0.8	3
950	A phase II study of gimatecan as salvage treatment in patients with advanced or metastatic soft tissue sarcoma (STS) relapsing after anthracycline / ifosfamide - based chemotherapy regimens. <i>Journal of Clinical Oncology</i> , 2007, 25, 10063-10063.	0.8	1
951	Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 10076-10076.	0.8	41
952	Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). <i>Journal of Clinical Oncology</i> , 2007, 25, 5044-5044.	0.8	16
953	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST) Update of the NCCN Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5, S-1-S-29.	2.3	360
954	Long term progression-free survival correlates with KIT/PDGFR mutational status in advanced GIST patients treated with imatinib (IM). <i>Journal of Clinical Oncology</i> , 2007, 25, 10053-10053.	0.8	1

#	ARTICLE	IF	CITATIONS
955	Serum Evaluation of a Panel of 10 Cytokines in Patients with Follicular Lymphoma: High Serum Level of TGF- β 2 Correlates with Good Prognosis, Independently of the FLIPI Score.. <i>Blood</i> , 2007, 110, 2604-2604.	0.6	0
956	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5 Suppl 2, S1-29; quiz S30.	2.3	201
957	23 Assessment of molecular determinants of development and treatment efficacy in radiation induced sarcoma (RIS) â€” eortc translational research project 01/01. <i>Radiotherapy and Oncology</i> , 2006, 78, S8-S9.	0.3	0
958	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2006, 42, 1093-1103.	1.3	810
959	Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTCâ€™ISGâ€™AGITG). <i>European Journal of Cancer</i> , 2006, 42, 2277-2285.	1.3	97
960	Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx ^{Â®}) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. <i>European Journal of Cancer</i> , 2006, 42, 2303-2309.	1.3	10
961	Sarcomas and malignant phyllodes tumours of the breast â€” A retrospective study. <i>European Journal of Cancer</i> , 2006, 42, 2715-2721.	1.3	104
962	Gastrointestinal Stromal Tumours: Consensus Statement on Diagnosis and Treatment. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 157-163.	1.8	115
963	ET-743: a novel agent with activity in soft-tissue sarcomas. <i>Current Opinion in Oncology</i> , 2006, 18, 347-353.	1.1	53
964	Incidence and prognostic value of tumour cells detected by RTâ€™PCR in peripheral blood stem cell collections from patients with Ewing tumour. <i>British Journal of Cancer</i> , 2006, 95, 1326-1333.	2.9	27
965	Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 254-267.	2.0	33
966	Gastrointestinal stromal tumors (GIST). <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 98-101.	0.9	5
967	CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. <i>BMC Cancer</i> , 2006, 6, 75.	1.1	31
968	Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: A retrospective analysis. <i>International Journal of Cancer</i> , 2006, 119, 706-711.	2.3	169
969	International study on low-grade primary central nervous system lymphoma. <i>Annals of Neurology</i> , 2006, 59, 755-762.	2.8	76
970	Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 6073-6078.	3.2	138
971	Management of Gastrointestinal Stromal Tumors in the Imatinib Era: Selected Case Studies. <i>Oncologist</i> , 2006, 11, 9-20.	1.9	54
972	Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. <i>British Journal of Cancer</i> , 2006, 94, 1066-1070.	2.9	34

#	ARTICLE	IF	CITATIONS
973	Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 9505-9505.	0.8	47
974	Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITC trial?. <i>Journal of Clinical Oncology</i> , 2006, 24, 9510-9510.	0.8	10
975	Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 9511-9511.	0.8	15
976	DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). <i>Journal of Clinical Oncology</i> , 2006, 24, 9522-9522.	0.8	20
977	Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphomaâ€™s Patients.. <i>Blood</i> , 2006, 108, 2984-2984.	0.6	0
978	Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. <i>Current Opinion in Oncology</i> , 2005, 17, 370-375.	1.1	8
979	Decision making process in oncology practice: Is the information available and what should it consist of?. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 54, 165-170.	2.0	6
980	Corrections to "Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20â€™21 March 2004, under the auspices of ESMOâ€™. <i>Annals of Oncology</i> , 2005, 16, 993.	0.6	14
981	Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 2233-2239.	0.8	188
982	ETâ€™743: A Novel Agent with Activity in Soft Tissue Sarcomas. <i>Oncologist</i> , 2005, 10, 827-832.	1.9	38
983	Early Variations of Circulating Interleukin-6 and Interleukin-10 Levels During Thoracic Radiotherapy Are Predictive for Radiation Pneumonitis. <i>Journal of Clinical Oncology</i> , 2005, 23, 8748-8756.	0.8	135
984	Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-Î± be better?. <i>Annals of Oncology</i> , 2005, 16, 1061-1068.	0.6	115
985	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factorâ€™2â€™ dependent manner. <i>Journal of Experimental Medicine</i> , 2005, 202, 1075-1085.	4.2	806
986	Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. <i>Radiotherapy and Oncology</i> , 2005, 76, 334-339.	0.3	56
987	P-700 Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis in patients with non-small cell lung cancer: A prospective study. <i>Lung Cancer</i> , 2005, 49, S302-S303.	0.9	0
988	Consensus meeting for the management of gastrointestinal stromal tumorsâ€™ Report of the GIST Consensus Conference of 20â€™21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005, 16, 566-578.	0.6	628
989	Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 576-584.	0.8	403
990	Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. <i>European Journal of Cancer</i> , 2005, 41, 1751-1757.	1.3	351

#	ARTICLE	IF	CITATIONS
991	Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. <i>European Journal of Surgical Oncology</i> , 2005, 31, 917-923.	0.5	80
992	A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update. <i>Journal of Clinical Oncology</i> , 2005, 23, 9033-9033.	0.8	29
993	Comparison of Outcome of Unselected Patients with Diffuse Large B-Cell Lymphoma Diagnosed before and after Approval of Rituximab in France in This Indication.. <i>Blood</i> , 2005, 106, 4766-4766.	0.6	0
994	International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients.. <i>Blood</i> , 2005, 106, 3343-3343.	0.6	7
995	A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor. <i>Cancer Research</i> , 2005, 65, 2-5.	0.4	17
996	Targeted cancer therapies. <i>Bulletin Du Cancer</i> , 2005, 92, E13-8.	0.6	15
997	Coexpression of CD40 and CD40L on B Lymphoma and Carcinoma Cells: an Autocrine Anti-Apoptotic Role. <i>Leukemia and Lymphoma</i> , 2004, 45, 1239-1245.	0.6	20
998	Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR- β in liposarcomas. , 2004, 120, 151-167.		14
999	Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 890-899.	0.8	290
1000	The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. <i>International Journal of Oncology</i> , 2004, 25, 407-12.	1.4	8
1001	Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6 From the Groupe Franais d'Immunothrapie. <i>Journal of Clinical Oncology</i> , 2004, 22, 2371-2378.	0.8	158
1002	Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2004, 5, 403-409.	2.0	11
1003	CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. <i>Cancer</i> , 2004, 101, 2675-2680.	2.0	83
1004	Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86?Langerin- and CD1a+CD86+Langerin+ phenotypes. <i>International Journal of Cancer</i> , 2004, 110, 710-720.	2.3	50
1005	IL-6 as an intracrine growth factor for renal carcinoma cell lines. <i>International Journal of Cancer</i> , 2004, 111, 653-661.	2.3	71
1006	Combination Treatment of Rituximab and Imatinib Mesylate for Simultaneous Relapse of MALT Lymphoma and a Gastrointestinal Stromal Tumor. <i>Leukemia and Lymphoma</i> , 2004, 45, 2353-2354.	0.6	3
1007	Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. <i>Annals of Oncology</i> , 2004, 15, 307-315.	0.6	174
1008	Les cellules dendritiques dans le microenvironnement tumoral. <i>Annales De Pathologie</i> , 2004, 24, 36-37.	0.1	0

#	ARTICLE	IF	CITATIONS
1009	Dendritic Cell Infiltration and Prognosis of Early Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 7466-7474.	3.2	399
1010	A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2004, 40, 1327-1331.	1.3	53
1011	Letter. <i>European Journal of Cancer</i> , 2004, 40, 1456-1457.	1.3	6
1012	Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. <i>European Journal of Cancer</i> , 2004, 40, 2071-2076.	1.3	104
1013	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet, The</i> , 2004, 364, 1127-1134.	6.3	1,561
1014	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004, 114, 379-388.	3.9	248
1015	Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. <i>Journal of Clinical Oncology</i> , 2004, 22, 9004-9004.	0.8	8
1016	Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 9006-9006.	0.8	15
1017	First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STs) in adults. <i>Journal of Clinical Oncology</i> , 2004, 22, 9015-9015.	0.8	2
1018	Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. <i>Journal of Clinical Oncology</i> , 2004, 22, 9004-9004.	0.8	9
1019	Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 9006-9006.	0.8	20
1020	First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STs) in adults. <i>Journal of Clinical Oncology</i> , 2004, 22, 9015-9015.	0.8	1
1021	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group. <i>Blood</i> , 2004, 104, 1372-1372.	0.6	0
1022	Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2003, 88, 1721-1726.	2.9	277
1023	Gastrointestinal Stromal Tumors: Biology and Treatment. <i>Oncology</i> , 2003, 65, 187-197.	0.9	112
1024	Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. <i>European Journal of Cancer</i> , 2003, 39, 64-69.	1.3	167
1025	Imatinib mesylate (STI-571 Glivec®, Gleevec®, ☺) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. <i>European Journal of Cancer</i> , 2003, 39, 2006-2011.	1.3	393
1026	Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. <i>European Journal of Cancer</i> , 2003, 39, 2021-2025.	1.3	94

#	ARTICLE	IF	CITATIONS
1027	Metastatic Soft Tissue Sarcoma in Adults. American Journal of Cancer, 2003, 2, 211-221.	0.4	21
1028	Risk Model Predictive of Severe Anemia Requiring RBC Transfusion After Chemotherapy in Pediatric Solid Tumor Patients. Journal of Clinical Oncology, 2003, 21, 4235-4238.	0.8	17
1029	Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. Journal of Clinical Oncology, 2003, 21, 266-272.	0.8	688
1030	Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. British Journal of Cancer, 2003, 88, 181-186.	2.9	103
1031	Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. European Journal of Cancer, 2003, 39, 2006-11.	1.3	101
1032	Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients. Journal of Clinical Oncology, 2002, 20, 24-36.	0.8	10
1033	A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients. British Journal of Cancer, 2002, 87, 1079-1085.	2.9	3
1034	A multicenter study of treatment of primary CNS lymphoma. Neurology, 2002, 58, 1513-1520.	1.5	322
1035	Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Annals of Oncology, 2002, 13, 531-538.	0.6	120
1036	Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer, 2002, 38, 556-559.	1.3	113
1037	Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients. Journal of Clinical Oncology, 2002, 20, 24-36.	0.8	17
1038	Commentary on "Advances in the Therapy of Primary Central Nervous System Lymphoma" Clinical Lymphoma and Myeloma, 2001, 1, 276.	2.1	1
1039	Randomised phase II trial of pegylated liposomal doxorubicin (DOXILÂ®/CAELYXÂ®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. European Journal of Cancer, 2001, 37, 870-877.	1.3	344
1040	Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule. European Journal of Cancer, 2001, 37, S34.	1.3	11
1041	Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment. Annals of Oncology, 2001, 12, 275-276.	0.6	1
1042	Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. International Journal of Radiation Oncology Biology Physics, 2001, 51, 419-425.	0.4	82
1043	Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. British Journal of Cancer, 2001, 85, 816-822.	2.9	64
1044	Osteosarcoma. British Journal of Cancer, 2001, 84, 78-80.	2.9	13

#	ARTICLE	IF	CITATIONS
1045	IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. <i>Cancer Research</i> , 2001, 61, 3096-104.	0.4	62
1046	Research controversies in management of oral mucositis. <i>Supportive Care in Cancer</i> , 2000, 8, 68-71.	1.0	45
1047	Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2000, 18, 2676-2684.	0.8	255
1048	High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation for Advanced Soft Tissue Sarcoma in Adults. <i>Journal of Clinical Oncology</i> , 2000, 18, 3643-3650.	0.8	63
1049	A Prospective Study Of The LMB Regimen For Diffuse Large Cell Non Hodgkin's Lymphoma In Adults. <i>Leukemia and Lymphoma</i> , 2000, 36, 525-532.	0.6	2
1050	Primary cerebral lymphomas: Unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. <i>Annals of Oncology</i> , 2000, 11, S39-S44.	0.6	13
1051	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2000, 36, 61-67.	1.3	125
1052	Title is missing!. <i>Annals of Oncology</i> , 2000, 11, 39-44.	0.6	16
1053	Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. <i>Groupe d'Etude des Lymphomes de l'Adulte. Haematologica</i> , 2000, 85, 502-7.	1.7	13
1054	Risk Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens. <i>Journal of Clinical Oncology</i> , 1999, 17, 2840-2840.	0.8	71
1055	High-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum] - doxorubicin in non-metastatic osteosarcoma of the extremity: A French multicentre pilot study. <i>Annals of Oncology</i> , 1999, 10, 1065-1072.	0.6	30
1056	Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. <i>British Journal of Cancer</i> , 1999, 79, 119-130.	2.9	56
1057	Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99 m skeletal angioscintigraphy. <i>European Radiology</i> , 1999, 9, 907-914.	2.3	34
1058	Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. , 1999, 85, 2589-2595.		259
1059	OSAD93: a multicentric pilot study of high dose ifosfamide (HDI) and CDDP in adult patients (PTS) with non metastatic osteosarcoma. <i>European Journal of Cancer</i> , 1999, 35, S270.	1.3	0
1060	Phase II study of raltitrexed (Tomudex™) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. <i>Anti-Cancer Drugs</i> , 1999, 10, 873-878.	0.7	17
1061	Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. <i>Cancer</i> , 1998, 82, 134-140.	2.0	40
1062	Les cytokines: outils et cibles privilégiés dans l'immuno-surveillance du cancer. <i>Annales De L'Institut Pasteur / Actualités</i> , 1998, 9, 121-130.	0.1	0

#	ARTICLE	IF	CITATIONS
1063	High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplantation, 1998, 21, 51-54.	1.3	41
1064	High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.. Journal of Clinical Oncology, 1998, 16, 864-871.	0.8	303
1065	Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients.. Journal of Clinical Oncology, 1998, 16, 3736-3743.	0.8	109
1066	Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor. Blood, 1998, 92, 4778-4791.	0.6	516
1067	A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy. Blood, 1998, 92, 405-410.	0.6	99
1068	Resistance to Cytotoxic Chemotherapy Induced by CD40 Ligand in Lymphoma Cells. Blood, 1998, 92, 3381-3387.	0.6	50
1069	Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor. Blood, 1998, 92, 4778-4791.	0.6	106
1070	A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy. Blood, 1998, 92, 405-410.	0.6	0
1071	A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood, 1998, 92, 405-10.	0.6	12
1072	Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood, 1998, 92, 3381-7.	0.6	19
1073	Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood, 1998, 92, 4778-91.	0.6	206
1074	Phase I study of interleukin-6 in children with solid tumours in relapse. European Journal of Cancer, 1997, 33, 1620-1626.	1.3	11
1075	Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.. Journal of Clinical Oncology, 1997, 15, 2945-2953.	0.8	205
1076	Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. British Journal of Cancer, 1997, 75, 283-286.	2.9	18
1077	The host's tumor immune conflict: from immunosuppression to resistance and destruction. Trends in Immunology, 1997, 18, 493-497.	7.5	327
1078	Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. , 1997, 72, 424-430.		219
1079	Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. , 1997, 72, 424.		7
1080	Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.. Journal of Clinical Oncology, 1996, 14, 636-643.	0.8	141

#	ARTICLE	IF	CITATIONS
1081	Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study.. <i>Journal of Clinical Oncology</i> , 1996, 14, 1697-1703.	0.8	96
1082	Tolerance Evaluation of L -asparaginase loaded in red blood cells. <i>European Journal of Clinical Pharmacology</i> , 1996, 51, 221-225.	0.8	51
1083	Serum interleukin-12 levels in patients undergoing allogeneic or autologous bone marrow transplantation. <i>European Cytokine Network</i> , 1996, 7, 389-94.	1.1	8
1084	Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. <i>Cancer Research</i> , 1996, 56, 5499-505.	0.4	146
1085	Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large- cell non-Hodgkin's lymphomas [letter; comment]. <i>Blood</i> , 1995, 86, 4702-4704.	0.6	17
1086	The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]. <i>Blood</i> , 1995, 86, 2922-2929.	0.6	119
1087	Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome. <i>European Journal of Cancer</i> , 1995, 31, 423.	1.3	3
1088	Prognostic factors in chordoma: Role of postoperative radiotherapy. <i>European Journal of Cancer</i> , 1995, 31, 2255-2259.	1.3	56
1089	Adoptive Immunotherapy with Interleukin-2 and LAK Cells or Gene Modified TIL in Patients with Renal Cell Carcinoma: Clinical and Laboratory Data. , 1995, , 249-253.		0
1090	Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. <i>Blood</i> , 1994, 84, 2472-2479.	0.6	114
1091	Local Production of Interleukin 6 by Renal Adenocarcinoma In Vivo. <i>Journal of the National Cancer Institute</i> , 1994, 86, 238-238.	3.0	19
1092	The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report. <i>Medical and Pediatric Oncology</i> , 1994, 22, 355-357.	1.0	15
1093	Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 1994, 69, 1111-1114.	2.9	46
1094	Pretreatment serum CRP and response to interleukin 2. <i>British Journal of Cancer</i> , 1994, 69, 200-201.	2.9	11
1095	Serum concentrations of cytokines in patients with Hodgkin's disease. <i>European Journal of Cancer</i> , 1994, 30, 321-324.	1.3	21
1096	Interleukin-2 Therapy: Report on 129 Patients and Three Different Schedules. , 1994, , 56-62.		1
1097	Failure of high-dose alkylating agents in osteosarcoma. Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 1994, 14, 665-6.	1.3	11
1098	Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. <i>British Journal of Cancer</i> , 1993, 67, 1136-1141.	2.9	36

#	ARTICLE	IF	CITATIONS
1099	Medulloblastoma in adults: Survival and prognostic factors. <i>Radiotherapy and Oncology</i> , 1993, 29, 301-307.	0.3	42
1100	Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. <i>British Journal of Cancer</i> , 1993, 68, 1036-1042.	2.9	16
1101	Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. <i>Blood</i> , 1993, 82, 2169-2174.	0.6	240
1102	Role of interleukin-6 in paraneoplastic thrombocytosis [letter]. <i>Blood</i> , 1993, 82, 2261-2262.	0.6	63
1103	Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. <i>Blood</i> , 1993, 82, 2169-74.	0.6	65
1104	Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. <i>British Journal of Cancer</i> , 1992, 65, 723-726.	2.9	21
1105	Tumor necrosis factor as an autocrine growth factor for neuroblastoma. <i>Cancer Research</i> , 1992, 52, 3194-200.	0.4	41
1106	High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. <i>Bone Marrow Transplantation</i> , 1992, 10, 405-8.	1.3	30
1107	Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. <i>Cancer Research</i> , 1992, 52, 3317-22.	0.4	320
1108	Management of pediatric non-Hodgkin's lymphoma. <i>Blood Reviews</i> , 1991, 5, 90-97.	2.8	14
1109	Functional interactions between interleukin-4, interleukin-2, and tumor necrosis factor- α for lymphokine-activated killer cell generation. <i>Journal of Clinical Laboratory Analysis</i> , 1990, 4, 54-58.	0.9	1
1110	Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation.. <i>Journal of Clinical Investigation</i> , 1990, 85, 1909-1913.	3.9	17
1111	TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2. <i>European Cytokine Network</i> , 1990, 1, 221-7.	1.1	4
1112	Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy. <i>European Cytokine Network</i> , 1990, 1, 141-7.	1.1	1
1113	Evidence for tumor necrosis factor- α involvement in the optimal induction of class I allospecific cytotoxic T cells. <i>Journal of Immunology</i> , 1990, 144, 4555-61.	0.4	37
1114	Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. <i>Cancer Research</i> , 1990, 50, 2371-4.	0.4	77
1115	Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients. <i>Journal of Biological Response Modifiers</i> , 1990, 9, 251-5.	0.3	4
1116	Functional interactions of IL2 and TNF in the differentiation of LGL into lak effectors. <i>International Journal of Cancer</i> , 1989, 44, 598-604.	2.3	29

#	ARTICLE	IF	CITATIONS
1117	Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 6875-6879.	3.3	74
1118	Correlation of the exposed-cell mortality with the transient cavitation noise in vitro. , 0, , .		1
1119	Prognosis and predictive value of KIT exon 11 deletion in GISTs. , 0, .		1